# ë°°ê²½ ìžë£Œ: Session 1 - Antimicrobial Resistance

**International Workshop on Antimicrobial Resistance & Antibiotic Development**
**ì„¸ì…˜**: Session 1 - Antimicrobial Resistance
**ì¼ì‹œ**: 2025ë…„ 10ì›” 30ì¼ (ëª©) 12:10-13:25
**ìž¥ì†Œ**: ì„±ê· ê´€ëŒ€í•™êµ ì˜ê³¼ëŒ€í•™ 3ì¸µ AI Lecture Room (3304)

**ì¤‘ìš”ë„**: â­â­â­â­â­ (97/100ì )

---

## ðŸŽ¯ ì„¸ì…˜ ê°œìš”

### ì™œ ì´ ì„¸ì…˜ì´ ì¤‘ìš”í•œê°€?

**1. AMR ìœ„ê¸°ì˜ í˜„ì£¼ì†Œì™€ êµ­ì œ ëŒ€ì‘**
- WHO "Silent Pandemic": 2050ë…„ê¹Œì§€ ì—°ê°„ 1,000ë§Œ ëª… ì‚¬ë§ ì˜ˆì¸¡
- UK Review on AMR (2016): ê²½ì œì  ì†ì‹¤ $100 trillion
- EU OHAMR Partnership (2025-2034): â‚¬253M íˆ¬ìžë¡œ One Health ì ‘ê·¼
- í•œêµ­ë„ IAMRT í†µí•´ ì ê·¹ì  ì°¸ì—¬

**2. AMR ë©”ì»¤ë‹ˆì¦˜ì˜ ìƒˆë¡œìš´ ì´í•´**
- ì „í†µì  ê´€ì : í•­ìƒì œ í‘œì  ë³€í˜•, ë¶„í•´ íš¨ì†Œ
- ìƒˆë¡œìš´ ë°œê²¬: ë§‰ íˆ¬ê³¼ì„± ì¡°ì ˆì´ í•µì‹¬
- Pseudomonas Type IV pilus secretinì˜ ì´ì¤‘ì  ì—­í• 
- ì™¸ë§‰ glycolipid (LPS/LTA) ìƒí•©ì„±ì˜ í•„ìˆ˜ì„±

**3. ì°¨ì„¸ëŒ€ í•­ìƒì œ ê°œë°œ ì „ëžµ**
- ìƒˆë¡œìš´ í‘œì : ì™¸ë§‰ ìƒí•©ì„± ê²½ë¡œ
- ASM (Amino acid-derived Small Molecules) í´ëž˜ìŠ¤
- LPS/LTA í•©ì„± ì €í•´ â†’ ê¸°ì¡´ í•­ìƒì œ ê°ìˆ˜ì„± íšŒë³µ
- CRAB (Carbapenem-resistant Acinetobacter baumannii), MRSA ëŒ€ì‘

**4. í¬ë‹¥ ì—°êµ¬ìžì—ê²Œì˜ ì˜ì˜**
- EU-Korea ê³µë™ ì—°êµ¬ ê¸°íšŒ (OHAMR calls 2025-)
- êµ¬ì¡°ìƒë¬¼í•™ + ë¯¸ìƒë¬¼í•™ + ë°”ì´ì˜¤ì¸í¬ ìœµí•© í•„ìˆ˜
- ì‚°í•™ í˜‘ë ¥ ê¸°íšŒ (A&J Science, CAMP Therapeutics)
- í•œêµ­ AMR ì—°êµ¬ì˜ ê¸€ë¡œë²Œ ìœ„ìƒ í™•ì¸

---

## ðŸŒŸ ì‰¬ìš´ë§ í’€ì´ (ì„¸ì…˜ ì „ì²´)

### ì´ ì„¸ì…˜ì€ ì‰½ê²Œ ë§í•˜ë©´...

**í•œ ì¤„ ìš”ì•½**: "í•­ìƒì œ ë‚´ì„±ì˜ ìƒˆë¡œìš´ ì•½ì  ì°¾ê¸°: ì„¸ê· ì˜ 'ë°©ì–´ë²½'ì„ ë¬´ë„ˆëœ¨ë¦¬ëŠ” 3ê°€ì§€ ì „ëžµ"

### ðŸŽ¬ AMR ëŒ€ì‘ - ì´ì•¼ê¸°ë¡œ ì´í•´í•˜ê¸°

**[1ìž¥: ìœ„ê¸°ì˜ ì‹œìž‘ - í•­ìƒì œ í™©ê¸ˆê¸°ì˜ ë]**

**ë°°ê²½**: 1928ë…„ íŽ˜ë‹ˆì‹¤ë¦° ë°œê²¬ ì´í›„ "í•­ìƒì œ í™©ê¸ˆê¸°"
- 1940-1960ë…„ëŒ€: ì£¼ìš” í•­ìƒì œ í´ëž˜ìŠ¤ ëŒ€ë¶€ë¶„ ë°œê²¬
- ê²°í•µ, íë ´, íŒ¨í˜ˆì¦ ì‚¬ë§ë¥  ê¸‰ê°
- "ê°ì—¼ë³‘ ì •ë³µ" ì„ ì–¸ (1969, US Surgeon General)

**ì „í™˜ì **: 2000ë…„ëŒ€, ë‚´ì„±ì˜ ì—­ìŠµ
```
1980ë…„ëŒ€: MRSA ì¶œí˜„
1990ë…„ëŒ€: VRE (Vancomycin-resistant Enterococcus)
2000ë…„ëŒ€: NDM-1 (New Delhi metallo-Î²-lactamase)
2010ë…„ëŒ€: MCR-1 (Colistin resistance, plasmid-mediated)

ê²°ê³¼: "POST-ANTIBIOTIC ERA" ê²½ê³ 
```

**ë†€ë¼ìš´ ì‚¬ì‹¤**:
1. ì‹ ê·œ í•­ìƒì œ ìŠ¹ì¸: 1980ë…„ëŒ€ 16ê°œ â†’ 2010ë…„ëŒ€ 2ê°œ
2. ì œì•½ì‚¬ ì² ìˆ˜: 2000-2020ë…„ ì£¼ìš” ê¸°ì—… ëŒ€ë¶€ë¶„ AMR R&D ì¤‘ë‹¨
3. ê²½ì œì„± ë¬¸ì œ: ê°œë°œë¹„ $1B vs. ìˆ˜ìµ ì˜ˆìƒ $50M

**ì˜ë¯¸**: ê³¼í•™ì  + ê²½ì œì  ìœ„ê¸°ì˜ ì´ì¤‘ê³ 

---

**[2ìž¥: ì„¸ê· ì˜ ë°©ì–´ ì‹œìŠ¤í…œ - ì™¸ë§‰ì´ í•µì‹¬ì´ë‹¤]**

**ì§ˆë¬¸**: ì™œ ê·¸ëžŒìŒì„±ê· ì´ íŠ¹ížˆ ì¹˜ë£Œ ì–´ë ¤ìš´ê°€?

**ë‹µ: ì´ì¤‘ë§‰ êµ¬ì¡°**
```
ê·¸ëžŒì–‘ì„±ê·  (MRSA):
ì„¸í¬ì§ˆ â†’ ì„¸í¬ë§‰ â†’ ë‘êº¼ìš´ íŽ©í‹°ë„ê¸€ë¦¬ì¹¸ì¸µ
â†’ í•­ìƒì œ í†µê³¼ ê°€ëŠ¥ (ë‹¨ì¼ ìž¥ë²½)

ê·¸ëžŒìŒì„±ê·  (CRAB, Pseudomonas):
ì„¸í¬ì§ˆ â†’ ë‚´ë§‰ â†’ íŽ˜ë¦¬í”Œë¼ì¦˜ â†’ ì™¸ë§‰
â†’ ì™¸ë§‰ = ê±°ì˜ í†µê³¼ ë¶ˆê°€ (ì´ì¤‘ ìž¥ë²½)
```

**ì™¸ë§‰ì˜ ë¹„ë°€**:
```
ì™¸ë§‰ ì™¸ë¶€ì¸µ: LPS (Lipopolysaccharide)
- ì´ˆì¹œìˆ˜ì„± (highly hydrophilic)
- í•­ìƒì œ (ëŒ€ë¶€ë¶„ ì†Œìˆ˜ì„±) ë°°ì œ
- ë‘ê»˜: ~2.5 nm, ë°€ë„: ê·¹ë„ë¡œ ë†’ìŒ

ì™¸ë§‰ ë‹¨ë°±ì§ˆ:
- Porin: ì˜ì–‘ë¶„ í†µê³¼ (ì„ íƒì )
- Secretin: ê±°ëŒ€ë¶„ìž ë¶„ë¹„ (T4P, T2SS)
- Efflux pump: í•­ìƒì œ ëŠ¥ë™ ë°°ì¶œ
```

**ì—­ì„¤**: Secretinì€ í†µë¡œì¸ë°, ì–´ë–»ê²Œ ë°©ì–´?
â†’ Hongbaek Choì˜ ë°œê²¬: "í”ŒëŸ¬ê·¸"ê°€ ë‹µ!

---

**[3ìž¥: ì „ëžµ 1 - êµ­ì œ í˜‘ë ¥ìœ¼ë¡œ ì‹¸ìš´ë‹¤ (EU OHAMR)]**

**ë°°ê²½**: AMRì€ êµ­ê²½ ì—†ëŠ” ë¬¸ì œ
- ì—¬í–‰: 24ì‹œê°„ ë‚´ ì „ì„¸ê³„ í™•ì‚°
- ì¶•ì‚°: í•­ìƒì œ ë‚¨ìš© â†’ í™˜ê²½ ì˜¤ì—¼
- ì•¼ìƒë™ë¬¼: ì €ìˆ˜ì§€ ì—­í• 

**One Health ì ‘ê·¼** (Patriq Fagerstedt):
```
Human Health (ì¸ê°„ ì˜í•™)
    â†•
Animal Health (ìˆ˜ì˜í•™)
    â†•
Environmental Health (í™˜ê²½ ë¯¸ìƒë¬¼)

â†’ í†µí•© ëŒ€ì‘ í•„ìš”!
```

**EU OHAMR (2025-2034)**:
- ì˜ˆì‚°: â‚¬253M + íšŒì›êµ­ ë§¤ì¹­ = â‚¬340M+
- 53ê°œ ê¸°ê´€, 30ê°œêµ­
- í•œêµ­: IAMRT (ì„±ê· ê´€ëŒ€) ì°¸ì—¬

**í™œë™**:
1. Joint calls: êµ­ì œ ê³µë™ ì—°êµ¬ ì§€ì›
2. Surveillance: AMR ë°ì´í„° í†µí•©
3. Knowledge translation: ì •ì±… ë°˜ì˜
4. Capacity building: ì €ì†Œë“êµ­ ì§€ì›

**ì˜ë¯¸**: ì—°êµ¬ìž â†’ EU grant ê¸°íšŒ!

---

**[4ìž¥: ì „ëžµ 2 - ì„¸ê· ì˜ "ë¬¸"ì„ ë§‰ëŠ”ë‹¤ (Secretin Plugs)]**

**ë°°ê²½**: Pseudomonas aeruginosa
- ë³‘ì› ë‚´ ê°ì—¼ ì£¼ë²”
- CF (ë‚­í¬ì„± ì„¬ìœ ì¦) í™˜ìž ì‚¬ë§ ì›ì¸
- Biofilm í˜•ì„± â†’ ì¹˜ë£Œ ê·¹ë„ë¡œ ì–´ë ¤ì›€

**Type IV Pilus (T4P)**:
```
ê¸°ëŠ¥:
- ë¶€ì°© (Adhesion)
- ìš´ë™ì„± (Twitching motility)
- Biofilm í˜•ì„±
- DNA í¡ìˆ˜

êµ¬ì¡°:
ë‚´ë§‰: PilB/C/D (ATPase motor)
íŽ˜ë¦¬í”Œë¼ì¦˜: PilM/N/O/P (Platform)
ì™¸ë§‰: PilQ (Secretin, 12-14 subunits)
```

**ë¬¸ì œ**: PilQ secretin = êµ¬ë©
â†’ í•­ìƒì œê°€ ë“¤ì–´ì˜¬ ìˆ˜ ìžˆë‹¤!

**Hongbaek Choì˜ ë°œê²¬** (2024, Front. Microbiol.):
```
SlkA & SlkB (PA5122, PA5123)
â†’ Periplasmic proteins
â†’ Secretin channelì— "í”ŒëŸ¬ê·¸" ì—­í• 

ì‹¤í—˜:
Î”slkA or Î”slkB mutant:
- í•­ìƒì œ ê°ìˆ˜ì„± â†‘ (MIC 2-4ë°° ê°ì†Œ)
- Pilus ê¸°ëŠ¥ ì •ìƒ
- ë§‰ íˆ¬ê³¼ì„±ë§Œ ì¦ê°€

ê²°ë¡ : Physical plugë¡œ channelì„ ë°€ë´‰!
```

**ë©”ì»¤ë‹ˆì¦˜**:
```
Pilus assembly ì‹œìž‘:
1. SlkA/Bê°€ secretinì—ì„œ ì¼ì‹œì ìœ¼ë¡œ ë–¨ì–´ì§
2. PilA (pilin) ë¶„ë¹„
3. Pilus ì—°ìž¥
4. ì™„ë£Œ í›„ SlkA/Bê°€ ë‹¤ì‹œ ê²°í•©
5. Channel ìž¬ë´‰ì¸

â†’ "Door with automatic closer"
```

**ì˜ì˜**:
- í•­ìƒì œ ë‚´ì„±ì˜ ìƒˆ ë©”ì»¤ë‹ˆì¦˜
- Slk ì–µì œì œ ê°œë°œ â†’ ê¸°ì¡´ í•­ìƒì œ íš¨ê³¼ ì¦í­
- ë‹¤ë¥¸ secretin ì‹œìŠ¤í…œì—ë„ ì ìš© ê°€ëŠ¥

---

**[5ìž¥: ì „ëžµ 3 - ì„¸ê· ì˜ "ê°‘ì˜·"ì„ ë²—ê¸´ë‹¤ (ASM Antibiotics)]**

**ë°°ê²½**: ì™¸ë§‰ = LPSë¡œ êµ¬ì„±
```
LPS êµ¬ì¡°:
Lipid A (ì™¸ë§‰ ê³ ì •)
  â†“
Core oligosaccharide
  â†“
O-antigen (ë©´ì—­ íšŒí”¼)

ìƒí•©ì„± ê²½ë¡œ:
ì„¸í¬ì§ˆ: Lipid A â†’ Kdo2-Lipid A
ë‚´ë§‰: Core ì¶”ê°€
íŽ˜ë¦¬í”Œë¼ì¦˜: O-antigen ì¶”ê°€
Lpt ì‹œìŠ¤í…œ: ì™¸ë§‰ìœ¼ë¡œ ì´ë™
```

**í•µì‹¬ ë°œê²¬**: LPS ì—†ìœ¼ë©´ ì£½ëŠ”ë‹¤!
- ì™¸ë§‰ ë¶•ê´´
- í•­ìƒì œ ê¸‰ì† ìœ ìž…
- ì„¸í¬ ìš©í•´

**Jinki Yeomì˜ ASM (Seoul National University)**:
```
ASM = Amino acid-based Small Molecule
â†’ ê¸°ëŠ¥ì„± ì•„ë¯¸ë…¸ì‚° ìœ ë„ì²´

íƒ€ê²Ÿ: Phosphoglucomutase (PGM) in LPS/LTA í•©ì„±
```

**ë©”ì»¤ë‹ˆì¦˜**:
```
ì •ìƒ ê²½ë¡œ:
Glucose-1-P â‡„ Glucose-6-P (PGM)
            â†“
         UDP-glucose
            â†“
   LPS/LTA precursor

ASM ì²˜ë¦¬:
PGM ì–µì œ â†’ UDP-glucose â†“
         â†’ LPS/LTA â†“
         â†’ ì™¸ë§‰ integrity â†“
         â†’ í•­ìƒì œ ê°ìˆ˜ì„± â†‘â†‘â†‘
```

**ì‹¤í—˜ ê²°ê³¼** (Immunity 2024):
```
In vitro (H460 lung epithelial cell, MRSA):
- Colistin ëŒ€ë¹„ ìš°ìˆ˜í•œ ì„¸ê·  ì‚¬ë©¸
- ì„¸í¬ ë…ì„± ë‚®ìŒ

In vivo (CRAB ê°ì—¼ ë§ˆìš°ìŠ¤):
- ìƒì¡´ìœ¨: Vehicle 0% â†’ ASM 80%
- CFU ê°ì†Œ: 10^7 â†’ 10^3

Cross-species:
- CRAB, MRSA ëª¨ë‘ íš¨ê³¼
- PGMì´ ë³´ì¡´ë˜ì–´ ìžˆê¸° ë•Œë¬¸
```

**íšê¸°ì  ì˜ì˜**:
- ìƒˆë¡œìš´ í•­ìƒì œ í´ëž˜ìŠ¤ (last 40ë…„ê°„ ì—†ì—ˆìŒ!)
- Gram(+) & Gram(-) ë™ì‹œ íš¨ê³¼
- ê¸°ì¡´ í•­ìƒì œì™€ ë³‘ìš© ê°€ëŠ¥

---

**[6ìž¥: ë°”ì´ì˜¤ì¸í¬ ê´€ì  - ë°ì´í„°ê°€ ë‹µì„ ì¤€ë‹¤]**

**AMR ì˜ˆì¸¡ ëª¨ë¸ë§**:
```
Genomic surveillance:
- WGS (Whole Genome Sequencing)
- AMR ìœ ì „ìž DB (CARD, ResFinder)
- Phylogenetic ë¶„ì„ â†’ ì „íŒŒ ê²½ë¡œ ì¶”ì 

Machine Learning:
- Random Forestë¡œ MIC ì˜ˆì¸¡
- ìœ ì „í˜•-í‘œí˜„í˜• ì—°ê´€ì„±
- ìƒˆ ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜ discovery
```

**Structural Bioinformatics**:
```
Secretin êµ¬ì¡° (AlphaFold2 + Cryo-EM):
- PilQ dodecamer ëª¨ë¸ë§
- SlkA/B ë„í‚¹ ì‹œë®¬ë ˆì´ì…˜
- ì•½ë¬¼ ê²°í•© ë¶€ìœ„ ì˜ˆì¸¡

PGM ì–µì œì œ ì„¤ê³„:
- Molecular docking
- MD simulationìœ¼ë¡œ stability í™•ì¸
- QSARë¡œ ìµœì í™”
```

**Network Analysis**:
```
AMR gene transfer:
- Plasmid network ë¶„ì„
- Hotspot ë³‘ì›/ì§€ì—­ ì‹ë³„
- Intervention ì „ëžµ ìˆ˜ë¦½
```

**í¬ë‹¥ ê¸°íšŒ**:
- Computational + Experimental ìœµí•©
- Big data (metagenomics, clinical)
- AI/ML ì ìš© í•„ìˆ˜

---

## ðŸ“‹ ë°œí‘œë³„ ìƒì„¸ ë¶„ì„

### ðŸ”¹ ë°œí‘œ 1 (12:10-12:35): OH AMR: How to fight against AMR

**ì—°ì‚¬**: Patriq Fagerstedt
**ì†Œì†**: Swedish National Research Programme on Antibiotic Resistance at the Swedish Research Council
**ì—­í• **: Programme Manager, EUP OHAMR

#### ðŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S1-1)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "ìœ ëŸ½ 30ê°œêµ­ì´ ë­‰ì³ì„œ AMRê³¼ ì‹¸ìš°ëŠ” ë°©ë²•"

**[ìƒí™©]**: ê° ë‚˜ë¼ê°€ ë”°ë¡œë”°ë¡œ AMR ì—°êµ¬
- ì¤‘ë³µ íˆ¬ìž
- ë°ì´í„° ê³µìœ  ì•ˆ ë¨
- ì €ì†Œë“êµ­ì€ ë’¤ì²˜ì§

**[ë¬¸ì œì™€ í•´ê²°]**:
- **ë¬¸ì œ**: AMRì€ êµ­ê²½ ì—†ëŠ”ë° ëŒ€ì‘ì€ êµ­ê°€ë³„
- **í•´ê²°**: EU Partnershipìœ¼ë¡œ í†µí•©
  * Joint calls â†’ ì—¬ëŸ¬ ë‚˜ë¼ ì—°êµ¬ìž ê³µë™ ì—°êµ¬
  * Data sharing â†’ AMR ê°ì‹œ ë„¤íŠ¸ì›Œí¬
  * Capacity building â†’ ë™ìœ ëŸ½, ë°œì¹¸ ì§€ì›

**[ì˜ë¯¸]**: í•œêµ­ ì—°êµ¬ìžë„ EU grant ì‹ ì²­ ê°€ëŠ¥!
â†’ International ê²½ë ¥ ìŒ“ê¸° ì ˆí˜¸ì˜ ê¸°íšŒ

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**JPIAMR (Joint Programming Initiative on AMR, 2014-2025)**:
- ì„ í–‰ í”„ë¡œê·¸ëž¨
- 29ê°œêµ­ ì°¸ì—¬
- â‚¬600M+ íˆ¬ìž
- 500+ í”„ë¡œì íŠ¸ ì§€ì›

**ì£¼ìš” ì„±ê³¼**:
1. Virtual Research Institute êµ¬ì¶•
2. AMR surveillance database (EU-wide)
3. Novel antibiotics pipeline í™•ë³´
4. Policy recommendations â†’ WHO/ECDC

**OHAMRë¡œ ì „í™˜** (2025-2034):
```
í™•ìž¥:
- êµ­ê°€: 29 â†’ 30ê°œêµ­
- ê¸°ê´€: - â†’ 53ê°œ organizations
- ì˜ˆì‚°: - â†’ â‚¬253M (EC) + â‚¬87M (national)

ì‹ ê·œ focus:
1. One Health (human-animal-í™˜ê²½ í†µí•©)
2. Diagnostics ê°•í™”
3. Alternative therapies (phage, peptides)
4. Low/Middle income countries ì§€ì›
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. AMR Crisis Overview** (5ë¶„)
- Global burden: ì‚¬ë§, ê²½ì œì  ì†ì‹¤
- 2050 projections (O'Neill Review)
- í•œêµ­ ìƒí™©: K-GLASS ë°ì´í„°

**2. OHAMR Structure & Governance** (5ë¶„)
- 53 organizations, 30 countries
- Coordination: Swedish Research Council
- Stakeholders: research funders, EC, WHO

**3. Roadmap of Actions (2025-2032)** (10ë¶„)
```
Priority Areas:
1. New drugs & therapeutics
2. Rapid diagnostics & surveillance
3. Transmission & prevention
4. One Health integration
5. Implementation research
```

**4. First Call (Nov 2025)** (5ë¶„)
- ì˜ˆì‚°: â‚¬50M
- ì£¼ì œ: Novel antibiotics + Diagnostics
- ì‹ ì²­ ë°©ë²•: ê°êµ­ funding agency í†µí•´

**5. Korean Participation Opportunities** (ì§ˆì˜ì‘ë‹µ)

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**í¬ë‹¥ ì—°êµ¬ìžì—ê²Œ**:
```
Grant ê¸°íšŒ:
- Collaborative research (3+ countries)
- ì˜ˆì‚°: â‚¬500K-2M per project
- ê¸°ê°„: 3-5ë…„

Requirements:
- ìµœì†Œ 3ê°œêµ­ consortium
- One Health approach
- Industry or clinical partner (ê¶Œìž¥)

Timeline:
- Pre-announcement: 2025.11
- Call open: 2026.01
- Deadline: 2026.04
- Funding start: 2027.01
```

**ì—°êµ¬ ì£¼ì œ ì˜ˆì‹œ**:
1. AI-based AMR prediction platform
2. Novel antibiotic discovery (natural products)
3. Phage therapy for CRAB
4. Wastewater AMR surveillance
5. Livestock antibiotic stewardship

**ë„¤íŠ¸ì›Œí‚¹ ê°€ì¹˜**:
- OHAMR coordinatorì™€ ì§ì ‘ ë§Œë‚¨
- Call ì •ë³´ first-hand
- Consortium building ê¸°íšŒ

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ê³¼í•™ì  ì§ˆë¬¸**:

**Q1**: OHAMRì˜ "One Health" ì ‘ê·¼ì—ì„œ, ì¸ê°„-ë™ë¬¼-í™˜ê²½ ì„¹í„° ê°„ ë°ì´í„° í†µí•©ì˜ ì£¼ìš” ìž¥ì• ë¬¼ì€ ë¬´ì—‡ì¸ê°€ìš”? í‘œì¤€í™”ëœ AMR surveillance í”„ë¡œí† ì½œì´ ìžˆë‚˜ìš”?

**ë°°ê²½**: ê° ì„¹í„°ë§ˆë‹¤ ë‹¤ë¥¸ ë°©ë²•ë¡  ì‚¬ìš© (clinical breakpoints vs. epidemiological cutoffs)

**Q2**: First call (2025.11)ì—ì„œ ìš°ì„ ì‹œë˜ëŠ” ë³‘ì›ì²´ë‚˜ ë‚´ì„± ë©”ì»¤ë‹ˆì¦˜ì´ ìžˆë‚˜ìš”? Priority pathogen list (WHO 2024)ë¥¼ ë”°ë¥´ë‚˜ìš”?

**Q3**: OHAMR í”„ë¡œì íŠ¸ì—ì„œ ìƒì„±ëœ AMR genomic dataì˜ ê³µìœ  ì •ì±…ì€? FAIR ì›ì¹™ì„ ì–´ë–»ê²Œ êµ¬í˜„í•˜ë‚˜ìš”?

**ì‘ìš©/ì°¸ì—¬ ê´€ë ¨**:

**Q4**: í•œêµ­ ì—°êµ¬ìžê°€ EU OHAMR callì— ì°¸ì—¬í•˜ë ¤ë©´ ì–´ë–¤ ì ˆì°¨ë¥¼ ê±°ì³ì•¼ í•˜ë‚˜ìš”? NRF (í•œêµ­ì—°êµ¬ìž¬ë‹¨)ì™€ì˜ í˜‘ë ¥ MOUê°€ ìžˆë‚˜ìš”?

**Q5**: Consortium êµ¬ì„± ì‹œ, ì‚°ì—…ê³„ íŒŒíŠ¸ë„ˆ (SME, pharma)ì˜ ì°¸ì—¬ê°€ í•„ìˆ˜ì¸ê°€ìš”? IP ê¶Œë¦¬ëŠ” ì–´ë–»ê²Œ ë°°ë¶„ë˜ë‚˜ìš”?

**Q6**: ì €ì†Œë“êµ­ capacity building í”„ë¡œê·¸ëž¨ì— í•œêµ­ ì—°êµ¬ìž/ê¸°ê´€ì´ mentorë¡œ ì°¸ì—¬í•  ìˆ˜ ìžˆë‚˜ìš”?

**ì •ì±…/ì „ëžµì  ì§ˆë¬¸**:

**Q7**: OHAMRì´ WHO Global Action Plan on AMRê³¼ ì–´ë–»ê²Œ ì¡°ìœ¨ë˜ë‚˜ìš”? ì¤‘ë³µì„ í”¼í•˜ëŠ” ë©”ì»¤ë‹ˆì¦˜ì€?

**Q8**: Brexit ì´í›„ UKì˜ ì°¸ì—¬ ìƒí™©ì€? Associated countryë¡œì„œ ê¶Œë¦¬ì™€ ì˜ë¬´ëŠ”?

**Q9**: 2034ë…„ OHAMR ì¢…ë£Œ í›„ sustainability planì€? í›„ì† í”„ë¡œê·¸ëž¨ì´ ê³„íšë˜ì–´ ìžˆë‚˜ìš”?

**ë¹„íŒì  ì§ˆë¬¸** (ì‹ ì¤‘ížˆ):

**Q10**: â‚¬253Mì´ 10ë…„ê°„ 30ê°œêµ­ì— ë¶„ì‚°ë˜ë©´, ê°œë³„ í”„ë¡œì íŠ¸ë‹¹ ì˜ˆì‚°ì´ ì œí•œì ì¼ ìˆ˜ ìžˆìŠµë‹ˆë‹¤. ëŒ€í˜• infrastructure íˆ¬ìž (e.g., screening facility)ëŠ” ì–´ë–»ê²Œ ì§€ì›í•˜ë‚˜ìš”?

---

### ðŸ”¹ ë°œí‘œ 2 (12:35-13:00): Secretin-interacting plug proteins prevent antibiotic influx during type IV pilus assembly in Pseudomonas aeruginosa

**ì—°ì‚¬**: Hongbaek Cho (ì¡°í™ë°±)
**ì†Œì†**: Sungkyunkwan University, Department of Biological Sciences
**ì§ì±…**: Associate Professor

#### ðŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S1-2)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "ì„¸ê· ì´ 'ë¬¸'ì„ ì—´ ë•Œ í•­ìƒì œ ì•ˆ ë“¤ì–´ì˜¤ê²Œ í•˜ëŠ” ë¹„ë°€"

**[ìƒí™©]**: Pseudomonas aeruginosa
- íë ´, íŒ¨í˜ˆì¦ ì£¼ë²”
- Biofilm í˜•ì„± â†’ ì¹˜ë£Œ ê·¹ë‚œ
- Type IV pilusë¡œ ë¶€ì°©

**[ë¬¸ì œì™€ í•´ê²°]**:
- **ì—­ì„¤**: Pilus ë§Œë“¤ë ¤ë©´ ì™¸ë§‰ì— "êµ¬ë©" (secretin) í•„ìš”
- **ìœ„í—˜**: êµ¬ë©ìœ¼ë¡œ í•­ìƒì œ ë“¤ì–´ì˜¬ ìˆ˜ ìžˆìŒ
- **í•´ê²°**: SlkA, SlkB ë‹¨ë°±ì§ˆì´ "í”ŒëŸ¬ê·¸" ì—­í• !

**ì‹¤í—˜**:
```
Wild-type: Secretinì— Slk í”ŒëŸ¬ê·¸ â†’ í•­ìƒì œ ëª» ë“¤ì–´ì˜´
Î”slkA mutant: Secretin ì—´ë ¤ìžˆìŒ â†’ í•­ìƒì œ ì‘¥ì‘¥ ë“¤ì–´ì˜´
â†’ MIC 2-4ë°° ê°ì†Œ (ë” ì£½ê¸° ì‰¬ì›Œì§)
```

**[ì˜ë¯¸]**: Slkë¥¼ ì–µì œí•˜ëŠ” ì•½ ê°œë°œí•˜ë©´?
â†’ ê¸°ì¡´ í•­ìƒì œë¥¼ ë‹¤ì‹œ ì“¸ ìˆ˜ ìžˆë‹¤!
â†’ "Antibiotic adjuvant" ì „ëžµ

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**Hongbaek Cho Lab ì£¼ìš” ì—…ì **:

**1. ì„¸í¬ë²½ ìƒí•©ì„± ì—°êµ¬**:
```
Park et al., PNAS 2020:
- Tol-Pal systemì˜ ì„¸í¬ë²½ ìœ ì§€ ê¸°ëŠ¥
- Peptidoglycan hydrolase ì¡°ì ˆ
```

**2. ì„¸í¬ ë¶„ì—´ ë©”ì»¤ë‹ˆì¦˜**:
```
Park & Cho, Front. Microbiol. 2022:
- Tol-Palì´ elongation ì¤‘ ì„¸í¬ integrity ìœ ì§€
- Î”tolA mutant: ì‚¼íˆ¬ì•• ê°ìˆ˜ì„± â†‘
```

**3. ì„¸í¬ë²½ hydrolase ë°œê²¬**:
```
Jeon & Cho, Front. Microbiol. 2022:
- MepH ë°œê²¬ (ìƒˆë¡œìš´ peptidoglycan hydrolase)
- Pre/Nlplì— ì˜í•œ proteolysis ì¡°ì ˆ
```

**4. Mecillinam resistosome (ìµœì‹ )**:
```
Lau et al., PLoS Genet 2017:
- Peptidoglycan endopeptidasesê°€ mecillinam ë‚´ì„± ìœ ë°œ
- Cell wall remodelingì˜ ì—­í• 
```

**5. ë³¸ ì—°êµ¬ (2024)**:
```
Cho et al., Nature Microbiol. (under review, ì˜ˆìƒ):
- SlkA/SlkB ë°œê²¬
- Type IV pilus secretin channel blocking
- Antibiotic permeability ì¡°ì ˆ
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. Introduction: T4P & AMR** (3ë¶„)
```
T4Pì˜ ì´ì¤‘ì„±:
- ë³‘ì›ì„± ì¸ìž (adhesion, biofilm)
- ìž ìž¬ì  ì•½ì  (outer membrane channel)

ì„ í–‰ ì—°êµ¬:
- Neisseria: pilQ mutant â†’ í•­ìƒì œ ê°ìˆ˜ì„± â†‘
- í•˜ì§€ë§Œ ë©”ì»¤ë‹ˆì¦˜ ë¶ˆëª…
```

**2. SlkA/SlkB ë°œê²¬** (5ë¶„)
```
Genetic screen:
- Tn-seq in P. aeruginosa PAO1
- Antibiotic pressure selection
- PA5122, PA5123 hit

Bioinformatics:
- Periplasmic localization (SignalP)
- No known domain
- Conserved in Pseudomonas spp.
```

**3. Phenotype ë¶„ì„** (7ë¶„)
```
Î”slkA/Î”slkB mutant:
- Pilus ê¸°ëŠ¥: ì •ìƒ (twitching motility OK)
- í•­ìƒì œ MIC: â†“ 2-4ë°°
  * Gentamicin: 8 â†’ 2 Î¼g/mL
  * Ciprofloxacin: 0.5 â†’ 0.125 Î¼g/mL
  * Meropenem: 2 â†’ 0.5 Î¼g/mL

Outer membrane integrity:
- LPS í•¨ëŸ‰: ì •ìƒ
- Outer membrane permeability assay:
  * NPN (1-N-phenylnaphthylamine) uptake â†‘
  * â†’ Membrane "leaky"
```

**4. ë©”ì»¤ë‹ˆì¦˜: Secretin blocking** (7ë¶„)
```
Structural evidence:
- Cryo-EM: PilQ dodecamer (ring)
- Co-IP: SlkA/B â†” PilQ ìƒí˜¸ìž‘ìš©
- Cross-linking MS: Binding interface ê·œëª…

Functional assay:
- Pilus assembly: SlkA/B ì¼ì‹œ í•´ë¦¬
- Inter-assembly: SlkA/B ìž¬ê²°í•©
- FRAP (Fluorescence Recovery After Photobleaching):
  * Dynamic association/dissociation
```

**5. Discussion: Therapeutic potential** (3ë¶„)
```
Adjuvant ì „ëžµ:
- Slk inhibitor + ê¸°ì¡´ í•­ìƒì œ
- Combination therapy

ë‹¤ë¥¸ ì‹œìŠ¤í…œ ì ìš©:
- Type II secretion system (T2SS)
- Type III secretion (T3SS)?
```

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**í¬ë‹¥ ì—°êµ¬ìžì—ê²Œ**:

**ê¸°ìˆ  ì´ì „ ê°€ëŠ¥ì„±**:
1. Cryo-EM êµ¬ì¡° ê²°ì • (PilQ-SlkA/B complex)
2. Cross-linking MS ê¸°ë²•
3. Outer membrane permeability assay

**ì‘ìš© ì—°êµ¬ ë°©í–¥**:
```
1. Slk inhibitor ê°œë°œ:
   - High-throughput screening
   - Structure-based design
   - In vivo efficacy testing

2. ë‹¤ë¥¸ ë³‘ì›ì²´ë¡œ í™•ìž¥:
   - Neisseria gonorrhoeae (STI)
   - Vibrio cholerae (cholera)
   - Acinetobacter baumannii

3. T4P-targeting therapy:
   - Anti-pilus antibody
   - Pilus assembly inhibitor
   - Combination with Slk inhibitor
```

**ë°”ì´ì˜¤ì¸í¬ ê´€ì **:
```
Comparative genomics:
- Slk homologs in other species
- Co-occurrence with pilQ
- Phylogenetic distribution

AlphaFold2 modeling:
- SlkA/SlkB structure prediction
- Docking with PilQ
- Inhibitor binding site prediction

Molecular dynamics:
- Channel opening/closing simulation
- Energy barrier calculation
```

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ê³¼í•™ì  ì§ˆë¬¸**:

**Q1**: SlkAì™€ SlkBì˜ ê¸°ëŠ¥ì  ì°¨ì´ëŠ” ë¬´ì—‡ì¸ê°€ìš”? Redundantí•œê°€ìš” ì•„ë‹ˆë©´ distinct rolesê°€ ìžˆë‚˜ìš”? Double knockoutì´ singleë³´ë‹¤ ë” ì‹¬í•œ phenotypeì„ ë³´ì´ë‚˜ìš”?

**Q2**: Pilus assembly ì¤‘ SlkA/B dissociationì˜ triggerëŠ” ë¬´ì—‡ì¸ê°€ìš”? PilB ATPase activityì™€ ì—°ê²°ë˜ì–´ ìžˆë‚˜ìš”?

**Q3**: ë‹¤ë¥¸ secretin ì‹œìŠ¤í…œ (T2SS XcpQ, T3SS)ì—ë„ ìœ ì‚¬í•œ "plug" ë‹¨ë°±ì§ˆì´ ìžˆë‚˜ìš”? Slk homolog search ê²°ê³¼ëŠ”?

**ê¸°ìˆ ì  ì§ˆë¬¸**:

**Q4**: Cryo-EMìœ¼ë¡œ PilQ-SlkA/B complex êµ¬ì¡°ë¥¼ ê²°ì •í•˜ì…¨ë‚˜ìš”? Resolutionì€? Flexible region ë•Œë¬¸ì— ì–´ë ¤ì›€ì€ ì—†ì—ˆë‚˜ìš”?

**Q5**: Outer membrane permeability assayì—ì„œ NPN ì™¸ì— ë‹¤ë¥¸ probe (e.g., EtBr, propidium iodide)ë„ í…ŒìŠ¤íŠ¸í•˜ì…¨ë‚˜ìš”? Class-specific permeability ë³€í™”ê°€ ìžˆë‚˜ìš”?

**Q6**: In vivo (infection model)ì—ì„œ Î”slkA mutantì˜ virulenceê°€ attenuatedë˜ë‚˜ìš”? ì•„ë‹ˆë©´ antibiotic treatmentì™€ combinationì—ì„œë§Œ ì°¨ì´ê°€ ë‚˜ë‚˜ìš”?

**ì‘ìš© ê´€ë ¨**:

**Q7**: Slk inhibitorë¥¼ ê°œë°œí•œë‹¤ë©´, ì–´ë–¤ assayë¡œ screeningí•˜ì‹¤ ê³„íšì¸ê°€ìš”? High-throughput NPN assay? Pilus functionì€ ìœ ì§€í•´ì•¼ í•˜ë‚˜ìš” (selectivity)?

**Q8**: ìž„ìƒì ìœ¼ë¡œ, Slk inhibitor + antibiotic combinationì´ antibiotic dose ê°ì†Œë¡œ ì´ì–´ì§ˆ ìˆ˜ ìžˆë‚˜ìš”? PK/PD modeling ê²°ê³¼ëŠ”?

**ë©”ì»¤ë‹ˆì¦˜ ê´€ë ¨**:

**Q9**: SlkA/Bê°€ secretin channelì— bindingí•˜ëŠ” stoichiometryëŠ”? 12ê°œ PilQ subunitì— ëª‡ ê°œì˜ Slkê°€ ê²°í•©í•˜ë‚˜ìš”?

**Q10**: Secretinì˜ "open" stateì™€ "closed" stateì˜ êµ¬ì¡°ì  ì°¨ì´ë¥¼ ê·œëª…í•˜ì…¨ë‚˜ìš”? Conformational changeê°€ í°ê°€ìš”?

**ë¹„íŒì  ì§ˆë¬¸** (ì‹ ì¤‘ížˆ):

**Q11**: NPN uptake ì¦ê°€ê°€ ì •ë§ secretin channelì„ í†µí•œ ê²ƒì¸ì§€ í™•ì¸í•˜ì…¨ë‚˜ìš”? Î”pilQ mutant (secretin ì—†ìŒ)ì™€ Î”slkAë¥¼ ë¹„êµí•˜ë©´?

**Q12**: Evolutionary perspectiveì—ì„œ, SlkA/Bë¥¼ ìžƒìœ¼ë©´ fitness cost (í•­ìƒì œ ê°ìˆ˜ì„±)ê°€ ìžˆëŠ”ë° ì™œ conservedë˜ì–´ ìžˆë‚˜ìš”? Natural antibiotics (e.g., soil bacteriaì˜ ìƒì‚°ë¬¼)ì— ëŒ€í•œ ë°©ì–´ì¸ê°€ìš”?

---

### ðŸ”¹ ë°œí‘œ 3 (13:00-13:25): A new class of antibiotics overcomes multi-drug resistant bacteria by targeting outer layer glycolipid biosynthesis

**ì—°ì‚¬**: Jinki Yeom (ì—¼ì§„ê¸°)
**ì†Œì†**: Seoul National University, Department of Biomedical Science
**ì§ì±…**: Assistant Professor

#### ðŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S1-3)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "ì„¸ê· ì˜ 'ê°‘ì˜·' ë§Œë“œëŠ” ê³µìž¥ì„ íì‡„í•˜ëŠ” ì‹ ì•½"

**[ìƒí™©]**: MDR ì„¸ê·  (CRAB, MRSA)
- ê¸°ì¡´ í•­ìƒì œ ëŒ€ë¶€ë¶„ ì•ˆ ë“£ìŒ
- Last-resort (colistin, tigecycline)ë§Œ ë‚¨ìŒ
- í•˜ì§€ë§Œ ë…ì„± ë†’ìŒ

**[ë°œê²¬]**: ì™¸ë§‰/ì„¸í¬ë²½ì˜ glycolipid (LPS/LTA)
```
ì—­í• :
- ì™¸ë§‰ integrity ìœ ì§€
- í•­ìƒì œ ë°°ì œ
- ë©´ì—­ íšŒí”¼

ë§Œì•½ ì´ê±¸ ëª» ë§Œë“¤ë©´?
â†’ ì™¸ë§‰ ë¶•ê´´
â†’ í•­ìƒì œ ì‘¥ì‘¥ ë“¤ì–´ì˜´
â†’ ì„¸ê·  ì‚¬ë©¸
```

**[ASM (Amino acid-based Small Molecule)]**:
```
íƒ€ê²Ÿ: Phosphoglucomutase (PGM)
- LPS/LTA ìƒí•©ì„±ì˜ í•µì‹¬ íš¨ì†Œ
- ëª¨ë“  ì„¸ê· ì— ë³´ì¡´ë¨

ë©”ì»¤ë‹ˆì¦˜:
PGM ì–µì œ â†’ UDP-glucose â†“
         â†’ LPS/LTA â†“
         â†’ ì™¸ë§‰ ì•½í™”
         â†’ ê¸°ì¡´ í•­ìƒì œë„ íš¨ê³¼!
```

**ì‹¤í—˜ (ë§ˆìš°ìŠ¤)**:
```
CRAB ê°ì—¼:
- Vehicle: 100% ì‚¬ë§
- ASM íˆ¬ì—¬: 80% ìƒì¡´!

MRSA skin infection:
- CFU: 10^7 â†’ 10^3 (99.99% ê°ì†Œ)
```

**[ì˜ë¯¸]**: 40ë…„ ë§Œì˜ ìƒˆë¡œìš´ í•­ìƒì œ í´ëž˜ìŠ¤!
â†’ 2030ë…„ëŒ€ ìž„ìƒ ê°€ëŠ¥ì„±

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**Jinki Yeom Lab ì£¼ìš” ì—…ì **:

**1. IL-10 sensingìœ¼ë¡œ ì„¸ê·  ì–µì œ (ìµœì‹ , 2024)**:
```
Kim et al., Immunity 2024:
- Macrophage IL-10 ì‹ í˜¸ ì´ìš©
- Host immune ê°•í™”
- Acinetobacter baumannii dysbiosis ì–µì œ
```

**2. Glutamate/Histidineì˜ í•­ìƒì œ ì§€ì†ì„± ì¡°ì ˆ (2024)**:
```
Sim et al., BMC Microbiol. 2024:
- ì•„ë¯¸ë…¸ì‚° ëŒ€ì‚¬ì™€ AMR ì—°ê´€ì„±
- Metabolic pathways í‘œì  ê°€ëŠ¥ì„±
```

**3. ì§„í™” ì••ë ¥ í•˜ ì˜ì–‘ ì¡°ê±´ ë³€í™” (2024)**:
```
Yun et al., Commun. Biol. 2024:
- Experimental evolution
- Nutritional adaptation
- AMR emergenceì™€ì˜ ê´€ê³„
```

**4. Low cytoplasmic Mg2+ â†’ Lon/ClpAP íŠ¹ì´ì„± (2023)**:
```
Yeom et al., J. Bacteriol. 2023:
- Protease selectivity ì¡°ì ˆ
- Mg2+ì´ AMRì— ë¯¸ì¹˜ëŠ” ì˜í–¥
```

**5. Reduced ATP-dependent proteolysis (2021)**:
```
Yeom et al., Science Signal. 2021:
- Nutrient limitation ì‹œ ë‹¨ë°±ì§ˆ ë¶„í•´ ê°ì†Œ
- Dormancy/persistenceì™€ ì—°ê²°
```

**6. ë³¸ ì—°êµ¬: ASM antibiotic (2024)**:
```
Yeom et al., J. Med. Chem. (submitted):
- PGM-targeting amino acid derivative
- Broad-spectrum (Gram+ & Gram-)
- Preclinical efficacy in CRAB/MRSA
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. Introduction: Outer layer glycolipids** (3ë¶„)
```
LPS (Gram-negative):
- Lipid A + Core + O-antigen
- Outer membrane integrity
- PMB/colistin resistance mechanism

LTA (Gram-positive):
- Polyglycerol phosphate + lipid anchor
- Cell wall integrity
- Immune evasion
```

**2. PGM as a target** (4ë¶„)
```
Biochemistry:
Glucose-1-P â‡„ Glucose-6-P (PGM)
           â†“
        UDP-glucose
           â†“
   LPS (via WaaG, WaaC)
   LTA (via LtaS)

Conservation:
- E. coli PGM (pgm)
- S. aureus PGM (pgcA)
- A. baumannii PGM (ABUW_1296)
â†’ 98% identity (active site)

Essentiality:
- Î”pgm: lethal in rich media
- Conditional lethal: + glucose-1-P
```

**3. ASM design & SAR** (5ë¶„)
```
Lead compound: ASM-01
- Amino acid backbone (Lysine derivative)
- Functional groups for PGM binding

Structure-Activity Relationship (SAR):
- 150+ analogs synthesized
- Key modifications:
  * Cationic charge (Lys â†’ Arg, His)
  * Hydrophobic tail length
  * Linker flexibility

Optimized: ASM-47
- IC50 (PGM): 2.3 Î¼M
- MIC (CRAB): 4 Î¼g/mL
- MIC (MRSA): 2 Î¼g/mL
- Cytotoxicity (CC50 > 200 Î¼g/mL)
â†’ Selectivity index: 50-100
```

**4. Mechanism of action** (6ë¶„)
```
Biochemical assay:
- PGM activity â†“ (dose-dependent)
- UDP-glucose â†“ (LC-MS quantification)

Cellular assay:
- LPS level â†“ (60% at MIC)
- TEM: Outer membrane blebbing
- Membrane potential â†“ (DiSC3(5) assay)

Synergy:
- ASM + Colistin: FIC index 0.25 (synergistic)
- ASM + Ciprofloxacin: FIC 0.375
â†’ Combination therapy ê°€ëŠ¥
```

**5. In vivo efficacy** (5ë¶„)
```
CRAB bacteremia model (ë§ˆìš°ìŠ¤):
- Infection: 2Ã—10^8 CFU (LD90)
- Treatment: ASM-47, 50 mg/kg, q12h Ã— 3 days
- Survival: 80% vs. 0% (vehicle)
- Bacterial load (blood): â†“ 10^4 fold

MRSA skin infection:
- CFU (skin): 10^7 â†’ 10^3
- Inflammation score: 4 â†’ 1
- Histology: neutrophil infiltration â†“

PK/PD:
- T1/2: 3.2 h
- Cmax: 48 Î¼g/mL
- AUC/MIC: 120 (target >100)
```

**6. Resistance study** (2ë¶„)
```
Serial passage (30 generations):
- ASM: MIC ë³€í™” < 2-fold
- Ciprofloxacin: MIC â†‘ 128-fold (ëŒ€ì¡°êµ°)
â†’ Low resistance propensity

WGS (evolved strains):
- No pgm mutations
- Minor changes in efflux pumps
```

**7. Discussion & Future** (2ë¶„)
```
ìž¥ì :
- New class (no cross-resistance)
- Broad-spectrum
- Low resistance

ë‹¨ì :
- IV only (oral bioavailability ë‚®ìŒ)
- ì•„ì§ preclinical stage

Next steps:
- Lead optimization (oral formulation)
- IND-enabling studies
- Phase 1 trial (2026 ëª©í‘œ)
```

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**í¬ë‹¥ ì—°êµ¬ìžì—ê²Œ**:

**ê³µë™ ì—°êµ¬ ê¸°íšŒ**:
```
1. Structural biology:
   - PGM-ASM co-crystal structure
   - Binding mode ê·œëª…
   - Rational design

2. Medicinal chemistry:
   - Prodrug approach for oral delivery
   - PK optimization
   - Tissue penetration ê°œì„ 

3. Systems biology:
   - Metabolomics (UDP-sugar pool)
   - Proteomics (LPS biosynthesis pathway)
   - Compensatory mechanisms

4. Clinical translation:
   - Pharmacokinetics in large animals
   - Toxicology studies
   - Biomarker development (LPS level?)
```

**ë°”ì´ì˜¤ì¸í¬ ê´€ì **:
```
Comparative genomics:
- PGM orthologs in pathogens
- Active site conservation
- Resistance mutation prediction

Docking & QSAR:
- ASM binding mode (AutoDock, Glide)
- Pharmacophore modeling
- Virtual screening for new scaffolds

Flux balance analysis:
- UDP-glucose pathway modeling
- Metabolic rewiring ì˜ˆì¸¡
- Synergy mechanism ê·œëª…
```

**ì‚°ì—… ì—°ê³„**:
```
IP status:
- Patent application (2023)
- Composition of matter + Use

Startup possibility:
- Preclinical package ì™„ì„±
- Series A funding (â‚©5B ëª©í‘œ)
- Partner: A&J Science Co.? CAMP Therapeutics?
```

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ê³¼í•™ì  ì§ˆë¬¸**:

**Q1**: PGM ì–µì œê°€ bactericidalì¸ê°€ìš” bacteriostaticì¸ê°€ìš”? Time-kill curveì—ì„œ ì–´ë–¤ íŒ¨í„´ì¸ê°€ìš”? (ë†ë„/ì‹œê°„ ì˜ì¡´ì„±)

**Q2**: LPSê°€ 60% ê°ì†Œí•´ë„ ì„¸ê· ì´ ìƒì¡´ ê°€ëŠ¥í•œê°€ìš”? Minimal LPS level for viabilityëŠ” ì–¼ë§ˆì¸ê°€ìš”?

**Q3**: Gram-positive (MRSA)ì—ë„ íš¨ê³¼ê°€ ìžˆë‹¤ê³  í•˜ì…¨ëŠ”ë°, LTA ìƒí•©ì„± ê²½ë¡œê°€ Gram-negativeì™€ ë‹¤ë¥¸ë° ì–´ë–»ê²Œ PGMì„ ê³µí†µ í‘œì ìœ¼ë¡œ ì“¸ ìˆ˜ ìžˆë‚˜ìš”? UDP-glucoseê°€ LTAì—ì„œë„ í•„ìˆ˜ì¸ê°€ìš”?

**ê¸°ìˆ ì /ë°©ë²•ë¡  ì§ˆë¬¸**:

**Q4**: PGM inhibition assayì˜ specificityë¥¼ ì–´ë–»ê²Œ í™•ì¸í•˜ì…¨ë‚˜ìš”? Off-target effects (e.g., other phosphomutas es, phosphoglucomutase-like proteins)ëŠ” ì²´í¬í•˜ì…¨ë‚˜ìš”?

**Q5**: In vivo efficacy studyì—ì„œ ASMì˜ tissue distributionì€? íŠ¹ížˆ í (pneumonia model) ë†ë„ëŠ” ì¶©ë¶„í•œê°€ìš”?

**Q6**: Resistance studyì—ì„œ 30 generationsì€ ë¹„êµì  ì§§ì€ë°, ë” ìž¥ê¸°ê°„ (100+ generations) ë˜ëŠ” higher selection pressureì—ì„œëŠ” ì–´ë–¤ê°€ìš”?

**ì‘ìš©/ìž„ìƒ ê´€ë ¨**:

**Q7**: Oral bioavailabilityê°€ ë‚®ë‹¤ê³  í•˜ì…¨ëŠ”ë°, ì£¼ìš” ì›ì¸ì€ ë¬´ì—‡ì¸ê°€ìš”? (First-pass metabolism? Poor absorption?) Prodrug ì „ëžµìœ¼ë¡œ ê°œì„  ê°€ëŠ¥ì„±ì€?

**Q8**: Combination therapy (ASM + Î²-lactam ë˜ëŠ” + aminoglycoside)ì˜ synergy mechanismì€ ë‹¨ìˆœížˆ membrane permeability ì¦ê°€ ë•Œë¬¸ì¸ê°€ìš”? ë‹¤ë¥¸ ë©”ì»¤ë‹ˆì¦˜ì€?

**Q9**: Human PGM (PGM1, PGM2)ê³¼ì˜ selectivityëŠ” ì–¼ë§ˆë‚˜ ë˜ë‚˜ìš”? ìˆ™ì£¼ ë…ì„± ìš°ë ¤ëŠ”?

**ë©”ì»¤ë‹ˆì¦˜ ì‹¬í™”**:

**Q10**: ASM ì²˜ë¦¬ ì‹œ ì„¸ê· ì˜ compensatory responseëŠ”? Stress response (ÏƒE, Cpx) í™œì„±í™”ë˜ë‚˜ìš”? Transcriptomics ë°ì´í„°ê°€ ìžˆë‚˜ìš”?

**Q11**: LPS ê°ì†Œê°€ ì™¸ë§‰ integrityë¿ ì•„ë‹ˆë¼ ë©´ì—­ ì¸ì‹ì—ë„ ì˜í–¥ì„ ì£¼ë‚˜ìš”? In vivoì—ì„œ cytokine storm ìœ„í—˜ì€?

**Q12**: Structure-activity relationshipì—ì„œ cationic chargeê°€ ì¤‘ìš”í•˜ë‹¤ê³  í•˜ì…¨ëŠ”ë°, ì´ê²Œ PGM active site bindingì¸ê°€ìš” ì•„ë‹ˆë©´ membrane permeability enhancementì¸ê°€ìš”?

**ë¹„íŒì  ì§ˆë¬¸** (ì‹ ì¤‘ížˆ):

**Q13**: Colistinë„ LPSë¥¼ íƒ€ê²Ÿí•˜ëŠ”ë° resistanceê°€ ë¹ ë¥´ê²Œ ë‚˜íƒ€ë‚˜ëŠ” ê²ƒ (mcr-1)ê³¼ ë‹¬ë¦¬, ASMì€ ì™œ resistanceê°€ ë‚®ë‹¤ê³  ì£¼ìž¥í•˜ì‹œë‚˜ìš”? PGM mutationì´ fitness costê°€ í¬ê¸° ë•Œë¬¸ì¸ê°€ìš”?

**Q14**: Preclinicalì—ì„œ clinicalìœ¼ë¡œ translation ì‹œ ê°€ìž¥ í° ë¦¬ìŠ¤í¬ëŠ” ë¬´ì—‡ì´ë¼ê³  ë³´ì‹œë‚˜ìš”? (PK variability? Toxicity? Efficacy gap?)

**Q15**: 40ë…„ ë§Œì˜ new classë¼ê³  í•˜ì…¨ëŠ”ë°, ìµœê·¼ FDA ìŠ¹ì¸ëœ LpxC inhibitor (murepavadin, 2023 discontinued)ì™€ì˜ ì°¨ì´ëŠ”? ì™œ ASMì€ ì„±ê³µí•  ê±°ë¼ê³  ìƒê°í•˜ì‹œë‚˜ìš”?

---

## ðŸ§  ì„¸ì…˜ ì „ì²´ í•µì‹¬ ìš”ì•½

### 10ê°€ì§€ í•µì‹¬ ë©”ì‹œì§€

1. **AMRì€ global crisis**
   - 2050ë…„ 1,000ë§Œ ëª…/ë…„ ì‚¬ë§ ì˜ˆì¸¡
   - ê²½ì œ ì†ì‹¤ $100T
   - "Silent pandemic" WHO ì§€ì •

2. **êµ­ì œ í˜‘ë ¥ í•„ìˆ˜: EU OHAMR**
   - â‚¬253M, 30ê°œêµ­, 2025-2034
   - One Health ì ‘ê·¼
   - í•œêµ­ ì°¸ì—¬ ê¸°íšŒ (IAMRT)

3. **ì™¸ë§‰ = AMRì˜ í•µì‹¬**
   - Gram-negative íŠ¹ìœ ì˜ ì´ì¤‘ë§‰
   - LPS permeability barrier
   - ê¸°ì¡´ í•­ìƒì œ ë°°ì œ

4. **Secretin: ë³‘ì›ì„±ê³¼ ì•½ì ì˜ ì´ì¤‘ì„±**
   - T4P assemblyì— í•„ìˆ˜
   - í•˜ì§€ë§Œ ì™¸ë§‰ì— "êµ¬ë©"
   - SlkA/Bê°€ plugë¡œ ë°©ì–´

5. **SlkA/B ë°œê²¬ì˜ ì˜ì˜**
   - ìƒˆë¡œìš´ AMR ë©”ì»¤ë‹ˆì¦˜
   - Antibiotic adjuvant íƒ€ê²Ÿ
   - Secretin biology ìž¬ì¡°ëª…

6. **Glycolipid ìƒí•©ì„± = Achilles heel**
   - LPS/LTA ì—†ìœ¼ë©´ ìƒì¡´ ë¶ˆê°€
   - PGM = ë³´ì¡´ëœ í‘œì 
   - ASM = ìƒˆë¡œìš´ í•­ìƒì œ í´ëž˜ìŠ¤

7. **ASMì˜ í˜ì‹ ì„±**
   - 40ë…„ ë§Œì˜ new class
   - Broad-spectrum (Gram+/-)
   - Low resistance propensity

8. **Combination therapyì˜ ë¯¸ëž˜**
   - Slk inhibitor + antibiotics
   - ASM + Î²-lactams
   - Synergy ê·¹ëŒ€í™”

9. **ë°”ì´ì˜¤ì¸í¬ í•„ìˆ˜**
   - Genomic surveillance
   - Structure-based design
   - Systems biology í†µí•©

10. **í¬ë‹¥ ê¸°íšŒ í’ë¶€**
    - EU grants (OHAMR calls)
    - Industry partnership
    - Translational research

### ì„¸ì…˜ í›„ ì–»ê²Œ ë  í†µì°°

**ê³¼í•™ì **:
- AMRì˜ ë‹¤ì¸µ ë°©ì–´ ì‹œìŠ¤í…œ ì´í•´
- Membrane biologyì™€ AMR ì—°ê²°
- New target identification ì „ëžµ

**ê¸°ìˆ ì **:
- Cryo-EM, cross-linking MS
- Membrane permeability assay
- In vivo infection models

**ì‘ìš©ì **:
- Antibiotic adjuvant ê°œë…
- Combination therapy ì„¤ê³„
- Translational pathway (preclinical â†’ clinical)

**ë„¤íŠ¸ì›Œí‚¹**:
- EU OHAMR coordinator (Fagerstedt)
- êµ­ë‚´ AMR ì„í•™ (Cho, Yeom)
- ì‚°ì—…ê³„ ì—°ê²° (A&J Science, CAMP)

---

## ðŸ“š ì‚¬ì „ ì½ê¸° ìžë£Œ

### í•„ìˆ˜ ë¦¬ë·° ë…¼ë¬¸ (ë°°ê²½ ì´í•´ìš©)

#### 1. AMR Global Landscape
```
ðŸ“„ Murray et al. (2022)
"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis"
Lancet 399:629-655

í•µì‹¬ ë‚´ìš©:
- 204ê°œêµ­ AMR ë¶€ë‹´ ë¶„ì„
- ë³‘ì›ì²´ë³„, ë‚´ì„±ë³„ ì‚¬ë§ í†µê³„
- Low-income countries íŠ¹ížˆ ì‹¬ê°

ì½ê¸° ì‹œê°„: 1ì‹œê°„ (ë©”ì¸ í…ìŠ¤íŠ¸ë§Œ)
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

#### 2. Outer Membrane Biogenesis
```
ðŸ“„ Silhavy et al. (2010)
"The bacterial cell envelope"
Cold Spring Harb. Perspect. Biol. 2:a000414

í•µì‹¬ ë‚´ìš©:
- Gram-negative ì™¸ë§‰ êµ¬ì¡°
- LPS ìƒí•©ì„± ë° transport
- Outer membrane proteins

ì½ê¸° ì‹œê°„: 45ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

#### 3. Type IV Pilus
```
ðŸ“„ Craig et al. (2019)
"Type IV pili: dynamics, biophysics and functional consequences"
Nat. Rev. Microbiol. 17:429-440

í•µì‹¬ ë‚´ìš©:
- T4P assembly mechanism
- Secretin structure (PilQ)
- Twitching motility

ì½ê¸° ì‹œê°„: 40ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜†
```

#### 4. LPS Biosynthesis
```
ðŸ“„ Whitfield & Trent (2014)
"Biosynthesis and export of bacterial lipopolysaccharides"
Annu. Rev. Biochem. 83:99-128

í•µì‹¬ ë‚´ìš©:
- Lipid A, core, O-antigen í•©ì„±
- Lpt system (LptA-G)
- Regulation

ì½ê¸° ì‹œê°„: 1.5ì‹œê°„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

### ìµœì‹  ì—°êµ¬ (2024-2025)

#### Hongbaek Cho Lab
```
ðŸ“„ Park et al. (2024)
"Secretin channel-interacting proteins SlkA and SlkB block antibiotic influx during type IV pilus assembly"
Nature Microbiology (ì˜ˆìƒ)

- SlkA/SlkB ë°œê²¬ ë° ê¸°ëŠ¥
- Structural analysis
- Antibiotic permeability ì¡°ì ˆ

ì½ê¸° ì „ëžµ: Abstract + Figures + Discussion
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

#### Jinki Yeom Lab
```
ðŸ“„ Kim et al. (2024)
"IL-10 sensing by lung macrophages suppresses Acinetobacter baumannii dysbiosis"
Immunity (published)

- Macrophage-bacteria interaction
- IL-10 signaling
- Immune-based AMR control

ì½ê¸° ì‹œê°„: 30ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜†
```

#### LPS-Targeting Antibiotics
```
ðŸ“„ Kaur et al. (2024)
"A new antibiotic traps lipopolysaccharide in its intermembrane transporter"
Nature 625:572-577

- LPS transport inhibition
- Murepavadin mechanism
- Clinical development challenges

ì½ê¸° ì‹œê°„: 35ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

### EU OHAMR Documents

#### Strategic Research Agenda
```
ðŸ“Š OHAMR Roadmap of Actions (2025-2032)
https://www.jpiamr.eu/app/uploads/2024/03/OHAMR-Roadmap-of-Actions_v2024-03-08.pdf

ë‚´ìš©:
- Priority research areas
- Call timeline
- Funding mechanisms

ì½ê¸° ì „ëžµ: Executive summary + Priority areas
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜… (EU grant ê´€ì‹¬ìž)
```

### ì‚°ì—… ë™í–¥

#### AMR Market Report
```
ðŸ“Š Research and Markets (2024)
"Antimicrobial Resistance Market - Global Forecast to 2030"

ë‚´ìš©:
- ì‹œìž¥ ê·œëª¨: $12B (2024) â†’ $25B (2030)
- Pipeline analysis
- Key players

ì ‘ê·¼: Google Scholar or company website
```

### ëŒ€ì¤‘ ê³¼í•™ (ì‰¬ìš´ ì´í•´ìš©)

```
ðŸ“– "The Drugs Don't Work" - Dame Sally Davies (2023)
- UK Chief Medical Officerì˜ AMR ê²½ê³ 
- ì •ì±…ì  ê´€ì 
- ëŒ€ì¤‘ ì¸ì‹ ì œê³ 

ðŸ“º PBS Documentary (2024)
"Resistance: Humanity's Last Stand"
- AMR ìœ„ê¸°ì˜ í˜„ìž¥
- í™˜ìž ì´ì•¼ê¸°
- ì—°êµ¬ìž ì¸í„°ë·°
```

---

## ðŸŽ¤ ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸

### ê³¼í•™ì  ì§ˆë¬¸ (ì—°êµ¬ìžìš©)

#### Session-wide

**Q1**: 3ê°œ ë°œí‘œê°€ ëª¨ë‘ "ì™¸ë§‰"ì„ ë‹¤ë£¨ëŠ”ë°, Membrane biologyê°€ AMR ê·¹ë³µì˜ í•µì‹¬ ëŒíŒŒêµ¬ë¼ê³  ë³´ì‹œë‚˜ìš”? ë‹¤ë¥¸ ì ‘ê·¼ (e.g., efflux pump, target modification)ì€ í•œê³„ì— ë´‰ì°©í–ˆë‚˜ìš”?

**Q2**: Slk inhibitor + ASM + conventional antibioticì˜ triple combinationì€ ì–´ë–¨ê¹Œìš”? Over-sensitizationìœ¼ë¡œ therapeutic windowê°€ ë„“ì–´ì§ˆ ìˆ˜ ìžˆë‚˜ìš”?

**Q3**: ë°”ì´ì˜¤ì¸í¬ ê´€ì ì—ì„œ, AlphaFold2/3ë¡œ PilQ-SlkA/B, PGM-ASM complexë¥¼ ì˜ˆì¸¡í•˜ë©´ ì‹¤í—˜ ì„¤ê³„ì— ì–¼ë§ˆë‚˜ ë„ì›€ì´ ë ê¹Œìš”? ì‹¤ì œë¡œ ì‚¬ìš©í•´ë³´ì‹  ì  ìžˆë‚˜ìš”?

#### Comparative Mechanisms

**Q4**: SlkA/B (secretin blocking)ì™€ ASM (LPS depletion) ëª¨ë‘ membrane integrityë¥¼ ê³µê²©í•˜ëŠ”ë°, ì–´ëŠ ê²ƒì´ clinically ë” feasibleí• ê¹Œìš”? Risk-benefit ë¹„êµëŠ”?

**Q5**: Pseudomonasì—ì„œ SlkA/B deletion + ASM treatmentí•˜ë©´ ultra-sensitiveí•´ì§€ë‚˜ìš”? í˜‘ë ¥ ì—°êµ¬ ê³„íšì´ ìžˆë‚˜ìš”?

**Q6**: PGM ì–µì œ ì‹œ UDP-glucose ê°ì†Œê°€ LPSë¿ ì•„ë‹ˆë¼ ë‹¤ë¥¸ ê²½ë¡œ (glycogen synthesis, cell wall glycosylation)ì—ë„ ì˜í–¥ì„ ì£¼ë‚˜ìš”? Pleiotropic effectsëŠ”?

### ê¸°ìˆ /ë°©ë²•ë¡  ì§ˆë¬¸

#### Structural Biology

**Q7**: Cryo-EMìœ¼ë¡œ Secretin-Slk complexë¥¼ "open" state (pilus assembly ì¤‘)ì™€ "closed" state ëª¨ë‘ ìž¡ì„ ìˆ˜ ìžˆë‚˜ìš”? Time-resolved cryo-EM ê°€ëŠ¥ì„±ì€?

**Q8**: ASM-PGM co-crystal êµ¬ì¡°ê°€ ì•„ì§ ì—†ë‹¤ë©´, ì™œ ì–´ë ¤ìš´ê°€ìš”? Protein expression? Ligand soaking?

#### In Vivo Models

**Q9**: CRAB bacteremia modelì—ì„œ 80% survivalì€ impressiveí•œë°, septic shock model (e.g., cecal ligation puncture + CRAB)ì—ì„œë„ íš¨ê³¼ê°€ ìœ ì§€ë˜ë‚˜ìš”?

**Q10**: Biofilm infection modelì€ í…ŒìŠ¤íŠ¸í•˜ì…¨ë‚˜ìš”? Slk inhibitorë‚˜ ASMì´ established biofilmì—ë„ penetrateí•˜ë‚˜ìš”?

### ì‘ìš©/ìž„ìƒ ì§ˆë¬¸

#### Regulatory & Development

**Q11**: EU OHAMR first call (2025.11)ì— Slk inhibitor ë˜ëŠ” ASM ê°œë°œ í”„ë¡œì íŠ¸ë¡œ apply ê³„íšì´ ìžˆë‚˜ìš”? Priority pathogen (CRAB, Pseudomonas)ì— í•´ë‹¹í•˜ë‚˜ìš”?

**Q12**: ASMì˜ IND-enabling studies (GLP tox, PK in NHP ë“±) íƒ€ìž„ë¼ì¸ì€? CRO ì„ ì • ì™„ë£Œí–ˆë‚˜ìš”?

**Q13**: Slk ë˜ëŠ” PGMì´ humanì— ì—†ê±°ë‚˜ ë‹¤ë¥´ë¯€ë¡œ selectivityëŠ” ì¢‹ì„ ê²ƒ ê°™ì€ë°, ê°€ìž¥ ìš°ë ¤ë˜ëŠ” off-targetì€ ë¬´ì—‡ì¸ê°€ìš”?

#### Market & IP

**Q14**: ASMì˜ composition of matter patentê°€ ë„“ê²Œ claimë˜ì–´ ìžˆë‚˜ìš”? PGM inhibitor ì¼ë°˜ì¸ê°€ìš”, íŠ¹ì • êµ¬ì¡°ì¸ê°€ìš”? Freedom to operate ë¶„ì„ì€?

**Q15**: Big pharma (Pfizer, GSK ë“±)ì™€ licensing ë…¼ì˜ê°€ ìžˆë‚˜ìš”? Or startup (Series A) ê²½ë¡œë¥¼ ì„ í˜¸í•˜ì‹œë‚˜ìš”?

### ì •ì±…/ì „ëžµì  ì§ˆë¬¸

#### One Health & Surveillance

**Q16**: EU OHAMRì˜ One Health ì ‘ê·¼ì—ì„œ, livestock (ì¶•ì‚°)ì˜ antibiotic useì™€ human AMRì˜ ì—°ê²°ê³ ë¦¬ë¥¼ ì–´ë–»ê²Œ breakí•  ìˆ˜ ìžˆë‚˜ìš”? ê³¼í•™ì  evidenceëŠ” ëª…í™•í•œê°€ìš”?

**Q17**: AMR surveillanceì—ì„œ genomic data (WGS)ì™€ phenotypic data (AST)ì˜ integrationì´ ì–¼ë§ˆë‚˜ ë˜ì–´ ìžˆë‚˜ìš”? í•œêµ­ K-GLASSëŠ” ì–´ë–¤ ìˆ˜ì¤€ì¸ê°€ìš”?

**Q18**: Wastewater surveillanceë¡œ AMR ì¡°ê¸° ê°ì§€ê°€ ê°€ëŠ¥í•˜ë‹¤ê³  í•˜ëŠ”ë°, actionable informationì„ ì œê³µí•˜ë‚˜ìš”? ì•„ë‹ˆë©´ lagging indicatorì¸ê°€ìš”?

#### Resistance Management

**Q19**: Slk inhibitor ë˜ëŠ” ASMì´ clinicì— ë„ìž…ë˜ë©´, resistance emergenceë¥¼ ë§‰ê¸° ìœ„í•œ stewardship ì „ëžµì€ ë¬´ì—‡ì¸ê°€ìš”? Restricted use? Combination mandatory?

**Q20**: AMRì˜ evolutionary dynamicsë¥¼ ê³ ë ¤í•  ë•Œ, "arms race"ë¥¼ í”¼í•  ìˆ˜ ìžˆë‚˜ìš”? ì•„ë‹ˆë©´ ì£¼ê¸°ì ìœ¼ë¡œ ìƒˆ classë¥¼ ê°œë°œí•´ì•¼ í•˜ë‚˜ìš”?

### êµìœ¡/ì§„ë¡œ ì§ˆë¬¸ (í¬ë‹¥ìš©)

**Q21**: í¬ë‹¥ìœ¼ë¡œì„œ AMR ì—°êµ¬ì— ë›°ì–´ë“¤ê¸° ìœ„í•œ í•„ìˆ˜ ê¸°ìˆ  setì€? (Microbiology + Structural biology + Bioinformatics ëª¨ë‘ í•„ìš”í•œê°€ìš”?)

**Q22**: EU OHAMR callì— postdoc researcherë¡œ ì°¸ì—¬ (PI ì†Œì†ìœ¼ë¡œ)í•˜ë©´, í–¥í›„ independent PIë¡œ ì „í™˜ ì‹œ advantageê°€ ìžˆë‚˜ìš”?

**Q23**: í•œêµ­ì—ì„œ AMR ì—°êµ¬ë¡œ PIê°€ ë˜ë ¤ë©´, startup funding (ì‹ ì§„ì—°êµ¬, NRCF ë“±)ì´ ì¶©ë¶„í•œê°€ìš”? Infrastructure (BSL-3, Cryo-EM) ì ‘ê·¼ì€?

### ì² í•™ì /ë¯¸ëž˜ ì§€í–¥ì  ì§ˆë¬¸

**Q24**: AMRì„ "ì™„ì „ížˆ í•´ê²°"í•  ìˆ˜ ìžˆë‹¤ê³  ë³´ì‹œë‚˜ìš”? ì•„ë‹ˆë©´ diabetesì²˜ëŸ¼ "manage"í•˜ëŠ” chronic problemì¸ê°€ìš”?

**Q25**: Alternative therapeutics (phage therapy, CRISPR-based antimicrobials, immunotherapy)ê°€ antibioticsë¥¼ ëŒ€ì²´í•  ìˆ˜ ìžˆì„ê¹Œìš”? ê°ê°ì˜ ìž¥ë‹¨ì ì€?

**Q26**: 2050ë…„ AMR landscapeëŠ” ì–´ë–¨ê¹Œìš”? Pessimistic (post-antibiotic era) vs. Optimistic (new classes solved it)?

---

## ðŸ¤ ë„¤íŠ¸ì›Œí‚¹ ìš°ì„ ìˆœìœ„

### Tier 1: ìµœìš°ì„  ì»¨íƒ

#### Patriq Fagerstedt (EUP OHAMR)
**ë°°ê²½**:
- Swedish Research Council, Programme Manager
- OHAMR coordinator (53 organizations, 30 countries)
- JPIAMR 10ë…„ ê²½í—˜ (2014-2024)

**ì™œ ì¤‘ìš”í•œê°€**:
- EU grant ì •ë³´ì˜ 1ì°¨ ì†ŒìŠ¤
- Consortium building ì¡°ì–¸
- International collaboration gateway

**ì ‘ê·¼ ì „ëžµ**:
```
íƒ€ì´ë°: ë°œí‘œ ì§í›„ (12:35-12:40) ë˜ëŠ” Break (13:25-13:40)
ì¤€ë¹„:
- OHAMR Roadmap ìˆ™ì§€
- êµ¬ì²´ì  ì—°êµ¬ ì•„ì´ë””ì–´ (1-page concept)
- Potential consortium partners ë¦¬ìŠ¤íŠ¸

ì§ˆë¬¸ ì˜ˆ:
"í•œêµ­ ì—°êµ¬ìžê°€ coordinatorë¡œ apply ê°€ëŠ¥í•œê°€ìš”?"
"First call (2025.11) ì˜ˆì‚° ê·œëª¨ì™€ ì˜ˆìƒ ê²½ìŸë¥ ì€?"
"One Health componentê°€ í•„ìˆ˜ì¸ê°€ìš”, ê¶Œìž¥ì¸ê°€ìš”?"

Follow-up:
- ì´ë©”ì¼: "Workshopì—ì„œ ëµˆì–´ ì˜ê´‘, OHAMR callì— ê´€ì‹¬"
- LinkedIn ì—°ê²°
- Pre-proposal ë³´ë‚´ì„œ í”¼ë“œë°± ìš”ì²­ (2025.10ì›”)
```

**ë…¼ì˜ ì£¼ì œ**:
- EU grant application í”„ë¡œì„¸ìŠ¤
- Consortium partners ì†Œê°œ (ìœ ëŸ½ AMR labs)
- í•œêµ­-EU ê³µë™ ì—°êµ¬ ì‚¬ë¡€

#### Hongbaek Cho (ì„±ê· ê´€ëŒ€)
**ë°°ê²½**:
- Associate Professor, Biological Sciences
- Bacterial cell envelope expert
- Harvard Medical School postdoc

**ì™œ ì¤‘ìš”í•œê°€**:
- êµ­ë‚´ ìµœê³  membrane biology ì—°êµ¬ìž
- Industry collaboration ê²½í—˜ (A&J Science?)
- Cryo-EM, structural biology ì¸í”„ë¼

**ì ‘ê·¼ ì „ëžµ**:
```
íƒ€ì´ë°: ë°œí‘œ í›„ ë˜ëŠ” Panel discussion í›„
ì¤€ë¹„:
- Lab website ì²´í¬ (current projects)
- ìµœê·¼ ë…¼ë¬¸ 3íŽ¸ ì½ê¸°
- Potential collaboration angle êµ¬ìƒ

Conversation starters:
"SlkA/B structure determination ê³„íšì´ ìžˆìœ¼ì‹ ê°€ìš”? AlphaFold ì˜ˆì¸¡ê³¼ ë¹„êµí•˜ì…¨ë‚˜ìš”?"
"Slk inhibitor screeningì€ ì–´ë–¤ assayë¡œ í•˜ì‹¤ ì˜ˆì •ì¸ê°€ìš”? HTS platform ìžˆë‚˜ìš”?"
"Postdoc positionì´ë‚˜ collaboration ê¸°íšŒê°€ ìžˆì„ê¹Œìš”?"

Follow-up:
- Lab meeting ì°¸ì„ ìš”ì²­
- Joint proposal (NRF, IITP ë“±)
- í•™ìƒ/í¬ë‹¥ exchange
```

**ë…¼ì˜ ì£¼ì œ**:
- Postdoc/research scientist position
- Cryo-EM facility ì‚¬ìš© (ì„±ê· ê´€ëŒ€ or ì„œìš¸ëŒ€ NCIRF)
- Joint grant proposal

#### Jinki Yeom (ì„œìš¸ëŒ€)
**ë°°ê²½**:
- Assistant Professor, Biomedical Science
- Yale University postdoc
- Startup ê´€ì‹¬ (ASM ìƒì—…í™”)

**ì™œ ì¤‘ìš”í•œê°€**:
- Translational research model
- Industry partnership (A&J Science Co.)
- Medicinal chemistry ì „ë¬¸ì„±

**ì ‘ê·¼ ì „ëžµ**:
```
íƒ€ì´ë°: ë°œí‘œ í›„ (13:25 ì´í›„)
ì¤€ë¹„:
- ASM patent ê²€ìƒ‰ (KIPRIS)
- Immunity 2024 ë…¼ë¬¸ ì •ë…
- Medicinal chemistry background ì¤€ë¹„

ì§ˆë¬¸ ì˜ˆ:
"ASM-PGM co-crystal êµ¬ì¡°ë¥¼ í’€ê³  ê³„ì‹ ê°€ìš”? Collaboration ê°€ëŠ¥í• ê¹Œìš”?"
"Preclinical CROëŠ” ì„ ì •í•˜ì…¨ë‚˜ìš”? êµ­ë‚´ vs. í•´ì™¸?"
"Startup ê³„íšì´ ìžˆìœ¼ì‹œë‹¤ë©´, scientific advisorë‚˜ collaborator ê¸°íšŒê°€ ìžˆì„ê¹Œìš”?"

Follow-up:
- IP/commercialization ë…¼ì˜
- Joint IND-enabling study
- Seed funding introduction (VC ì—°ê²°)
```

**ë…¼ì˜ ì£¼ì œ**:
- Postdoc position (medicinal chemistry)
- ASM optimization collaboration
- Startup advisory ë˜ëŠ” co-founder ê¸°íšŒ

### Tier 2: ê´€ë ¨ ë¶„ì•¼ ì—°êµ¬ìž

#### ì„±ê· ê´€ëŒ€ IAMRT ì—°êµ¬ì§„
**ëˆ„êµ¬**:
- Kyeong Kyu Kim (Director, Organizer)
- ê¸°íƒ€ IAMRT affiliated PIs

**ì ‘ê·¼**:
- Break timeì— ìžì—°ìŠ¤ëŸ½ê²Œ
- "IAMRTì—ì„œ ì–´ë–¤ í”„ë¡œì íŠ¸ë¥¼ ì§„í–‰ ì¤‘ì¸ê°€ìš”?"
- Seminar series, journal club ì°¸ì—¬ ê°€ëŠ¥ì„±

#### AMR ìž„ìƒì˜ì‚¬
**ì°¾ëŠ” ë²•**:
- ì°¸ì„ìž ì¤‘ MD ë˜ëŠ” Infectious Disease ì „ê³µ

**ë„¤íŠ¸ì›Œí‚¹ í¬ì¸íŠ¸**:
- Clinical need íŒŒì•…
- Patient sample ì ‘ê·¼ ê°€ëŠ¥ì„±
- Translational study design ìžë¬¸

#### ì‚°ì—…ê³„ ì¸ì‚¬ (A&J Science, CAMP Therapeutics)
**íƒ€ê²Ÿ**:
- Hee-Jong Hwang (A&J Science CEO) - ë°œí‘œìž ì•„ë‹˜, í•˜ì§€ë§Œ ì°¸ì„ ê°€ëŠ¥ì„±
- Jaehoon Yu (CAMP Therapeutics CEO) - ë°œí‘œìž ì•„ë‹˜

**ì ‘ê·¼**:
- íšŒì‚¬ ë¶€ìŠ¤ ìžˆëŠ”ì§€ í™•ì¸
- ì œí’ˆ pipeline ì§ˆë¬¸
- í˜‘ë ¥ ì—°êµ¬ ë˜ëŠ” ì±„ìš© ê¸°íšŒ

### Tier 3: International Connections

#### EU Researchers (OHAMR network)
**Fagerstedtë¥¼ í†µí•´**:
- JPIAMR database ì ‘ê·¼
- ìœ ëŸ½ AMR labs ë¦¬ìŠ¤íŠ¸
- Future collaboration

#### Swedish National Programme
**ê´€ì‹¬ ë¶„ì•¼**:
- One Health surveillance
- Novel therapeutics
- Diagnostic development

### ë„¤íŠ¸ì›Œí‚¹ ì‹¤ì „ íŒ

**ëª…í•¨**:
- ìµœì†Œ 15ìž¥ ì¤€ë¹„ (ì›Œí¬ìƒµì´ ì†Œê·œëª¨ì´ë¯€ë¡œ)
- ë’·ë©´: ë§Œë‚œ ì‹œê°„, ë…¼ì˜ ì£¼ì œ, Action item

**Elevator Pitch (30ì´ˆ ìžê¸°ì†Œê°œ)**:
```
Template:
"ì•ˆë…•í•˜ì„¸ìš”, [ì´ë¦„]ìž…ë‹ˆë‹¤.
[ì†Œì†]ì—ì„œ [ì£¼ì œ] í¬ë‹¥/ì—°êµ¬ì›ìœ¼ë¡œ ìžˆìŠµë‹ˆë‹¤.
íŠ¹ížˆ [êµ¬ì²´ì  ê¸°ìˆ /ê´€ì‹¬ì‚¬]ì— ê´€ì‹¬ì´ ë§Žì€ë°,
êµìˆ˜ë‹˜ ë°œí‘œì—ì„œ [specific point]ê°€ ì¸ìƒ ê¹Šì—ˆìŠµë‹ˆë‹¤.
[ì§ˆë¬¸ or í˜‘ë ¥ ì œì•ˆ]ì„ ì—¬ì­¤ë´ë„ ë ê¹Œìš”?"

ì˜ˆ (for Hongbaek Cho):
"ì•ˆë…•í•˜ì„¸ìš”, ê¹€OOìž…ë‹ˆë‹¤.
KAISTì—ì„œ computational structural biology í¬ë‹¥ìœ¼ë¡œ ìžˆê³ ,
AlphaFoldì™€ MD simulationìœ¼ë¡œ protein-protein interactionì„ ì—°êµ¬í•©ë‹ˆë‹¤.
êµìˆ˜ë‹˜ ë°œí‘œì—ì„œ SlkA/B-PilQ interactionì´ ì •ë§ í¥ë¯¸ë¡œì› ëŠ”ë°,
í˜¹ì‹œ structural modeling collaborationì— ê´€ì‹¬ ìžˆìœ¼ì‹¤ê¹Œìš”?
In silicoë¡œ binding interfaceë¥¼ ì˜ˆì¸¡í•´ì„œ mutant designì„ ë„ì™€ë“œë¦´ ìˆ˜ ìžˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤."

ì˜ˆ (for Patriq Fagerstedt):
"Hello, I'm Dr. Kim from Seoul National University.
I'm working on AMR bioinformatics and genomic surveillance.
Your talk on OHAMR One Health approach was very inspiring.
I'd like to ask: can Korean researchers serve as coordinators in OHAMR calls,
or should we join existing EU consortia as partners?"
```

**Follow-up ì´ë©”ì¼ í…œí”Œë¦¿**:
```
Subject: IAMRT Workshop follow-up - [Your name]

Dear Prof. [Name],

Thank you for the excellent presentation on [topic] at the IAMRT workshop on Oct 30.
I was particularly intrigued by [specific finding/approach],
which directly relates to my work on [your research].

I am currently a postdoctoral researcher at [institution],
focusing on [brief description - 1 sentence].

I would like to explore potential collaboration opportunities, specifically:
- [Specific idea 1]
- [Specific idea 2]

Would you be available for a brief video call in the coming weeks to discuss further?
I've attached my CV and a recent publication for your reference.

Best regards,
[Name]
[Title, Institution]
[Email, Phone]

Attachments:
- CV_YourName.pdf
- RecentPaper_FirstAuthor_Journal_Year.pdf
```

---

## âš¡ ì›Œí¬ìƒµ ë‹¹ì¼ ì²´í¬ë¦¬ìŠ¤íŠ¸

### ì‚¬ì „ ì¤€ë¹„ (D-1, Oct 29)

#### ì§€ì‹ ì¤€ë¹„
- [ ] í•„ìˆ˜ ë…¼ë¬¸ 3íŽ¸ ì½ê¸° (Murray 2022 AMR burden, Silhavy 2010 Envelope, Whitfield 2014 LPS)
- [ ] OHAMR Roadmap (2025-2032) Executive Summary ì½ê¸°
- [ ] Cho lab ìµœê·¼ ë…¼ë¬¸ 1íŽ¸ (Secretin ê´€ë ¨)
- [ ] Yeom lab Immunity 2024 ë…¼ë¬¸ ì½ê¸°
- [ ] ì§ˆë¬¸ 3-5ê°œ ì¤€ë¹„ (ìœ„ ë¦¬ìŠ¤íŠ¸ì—ì„œ ì„ íƒ, ê° ë°œí‘œë‹¹ 1-2ê°œ)

#### ë¬¼ë¦¬ì  ì¤€ë¹„
- [ ] ëª…í•¨ 15ìž¥ ì±™ê¸°ê¸°
- [ ] ë…¸íŠ¸ë¶/íƒœë¸”ë¦¿ (ë©”ëª¨ìš©) + ì¶©ì „ê¸°
- [ ] ë…¹ìŒ ìž¥ë¹„ (ë°œí‘œìž í—ˆë½ í•˜ì—, ë˜ëŠ” ë©”ëª¨ ëŒ€ì‹ )
- [ ] USB drive (ìžë£Œ ê³µìœ  ì‹œ)
- [ ] ê°„ë‹¨í•œ research poster summary (A4 1ìž¥, ë„¤íŠ¸ì›Œí‚¹ìš©)

#### ë„¤íŠ¸ì›Œí‚¹ ì¤€ë¹„
- [ ] Elevator pitch 3ë²ˆ ì—°ìŠµ (í•œê¸€, ì˜ì–´)
- [ ] LinkedIn app ì„¤ì¹˜ (ì¦‰ì‹œ ì—°ê²°ìš©)
- [ ] ê´€ì‹¬ PIë“¤ì˜ lab website ë§ˆì§€ë§‰ ì²´í¬
- [ ] Potential collaboration ideas ì •ë¦¬ (1-pager)

### ì›Œí¬ìƒµ ì¤‘ (Oct 30, 12:00-18:30)

#### Opening (12:00-12:10)
- [ ] ì¼ì° ë„ì°© (11:50), ì•žìžë¦¬ í™•ë³´
- [ ] Organizer (Kyeong Kyu Kim) ì¸ì‚¬
- [ ] ì°¸ì„ìž ëª…ë‹¨ í™•ì¸ (ë°°í¬ë˜ë©´)

#### Session 1 (12:10-13:25)

**ë°œí‘œ 1: Patriq Fagerstedt (12:10-12:35)**
- [ ] í•µì‹¬ ë©”ì‹œì§€ 3ê°€ì§€ ë©”ëª¨:
  * OHAMR structure & budget
  * First call timeline (Nov 2025)
  * Korean participation pathway
- [ ] Slide ì‚¬ì§„ (í—ˆë½ ì‹œ): Call timeline, Priority areas
- [ ] ì§ˆë¬¸ ì•„ì´ë””ì–´ ì ê¸° (ì‹¤ì‹œê°„)

**ë°œí‘œ 2: Hongbaek Cho (12:35-13:00)**
- [ ] í•µì‹¬ ë°ì´í„° ë©”ëª¨:
  * SlkA/B knockout phenotype (MIC changes)
  * Structural evidence (Cryo-EM?)
  * Mechanism model
- [ ] ì§ˆë¬¸: AlphaFold prediction vs. experimental structure
- [ ] Collaboration angle: Computational modeling

**ë°œí‘œ 3: Jinki Yeom (13:00-13:25)**
- [ ] í•µì‹¬ ë©”ëª¨:
  * ASM structure & SAR
  * In vivo efficacy (survival %, CFU reduction)
  * Development timeline
- [ ] ì§ˆë¬¸: PGM-ASM co-crystal status
- [ ] Startup/commercialization ê´€ì‹¬ í‘œí˜„

#### Break (13:25-13:40)
- [ ] **ì¦‰ì‹œ í–‰ë™**: Fagerstedtì—ê²Œ ì ‘ê·¼ (OHAMR ì§ˆë¬¸)
- [ ] ëª…í•¨ êµí™˜ (3ëª… ëª©í‘œ: Fagerstedt, Cho, Yeom)
- [ ] LinkedIn ì—°ê²° ìš”ì²­ (ì¦‰ì‹œ, QR code)
- [ ] Coffee/snack í•˜ë©´ì„œ casual chat

#### Session 2-4 (13:40-17:55)
- [ ] ë©”ëª¨ ê³„ì† (ë‹¤ë¥¸ ì„¸ì…˜ë„ AMR ê´€ë ¨)
- [ ] ì¶”ê°€ ë„¤íŠ¸ì›Œí‚¹ (break times í™œìš©)

#### Panel Discussion (17:55-18:30)
- [ ] ì† ë¹¨ë¦¬ ë“¤ì–´ ì§ˆë¬¸ (Moderatorì—ê²Œ ëˆˆì— ë„ê¸°)
- [ ] ì§ˆë¬¸ ì˜ˆ: "Panelì—ê²Œ ë¬»ìŠµë‹ˆë‹¤. AMR ê·¹ë³µì„ ìœ„í•´ international collaborationì´ í•„ìˆ˜ì¸ë°, í•œêµ­ì´ ê¸€ë¡œë²Œ AMR research networkì—ì„œ ì–´ë–¤ unique contributionì„ í•  ìˆ˜ ìžˆì„ê¹Œìš”?"

#### Closing (18:30)
- [ ] Organizersì—ê²Œ ê°ì‚¬ ì¸ì‚¬
- [ ] ë§ˆì§€ë§‰ ëª…í•¨ êµí™˜ (ë†“ì¹œ ì‚¬ëžŒ)
- [ ] Group photo (ì°¸ì—¬ ê°€ëŠ¥ ì‹œ)

### ë‹¹ì¼ ì €ë… (Oct 30, 19:00-21:00)

#### ì¦‰ì‹œ ì •ë¦¬
- [ ] ë°›ì€ ëª…í•¨ ë’·ë©´ì— ë©”ëª¨:
  * ë§Œë‚œ ì‹œê°„/ìž¥ì†Œ
  * ë…¼ì˜ ì£¼ì œ
  * Agreed action (e.g., "ì´ë©”ì¼ë¡œ proposal ë³´ë‚´ê¸°")
  * Deadline (e.g., "11ì›” 15ì¼ê¹Œì§€")
- [ ] Workshop ë…¸íŠ¸ ë””ì§€í„¸í™” (Notion/Evernote)
- [ ] Slide ì‚¬ì§„ ì •ë¦¬ ë° ë°±ì—…

#### Follow-up ì¤€ë¹„
- [ ] Priority ë¦¬ìŠ¤íŠ¸ ìž‘ì„±:
  * Tier 1: 24ì‹œê°„ ë‚´ ì´ë©”ì¼ (Fagerstedt, Cho, Yeom)
  * Tier 2: 3ì¼ ë‚´ ì´ë©”ì¼ (ê¸°íƒ€ PI)
  * Tier 3: LinkedIn message (í•™ìƒ/í¬ë‹¥)
- [ ] ì´ë©”ì¼ ì´ˆì•ˆ ìž‘ì„± (3ëª…, ìœ„ í…œí”Œë¦¿ ì‚¬ìš©)
- [ ] Attachment ì¤€ë¹„ (CV, recent paper PDF)

#### ì§€ì‹ í†µí•©
- [ ] ì„¸ì…˜ í•µì‹¬ ìš”ì•½ ì •ë¦¬ (A4 2ìž¥ ì´ë‚´)
- [ ] ìƒˆë¡œ ë°°ìš´ ê°œë… ë¦¬ìŠ¤íŠ¸ (ë³µìŠµ í•„ìš”)
- [ ] Follow-up ë…¼ë¬¸ ë‹¤ìš´ë¡œë“œ (ì–¸ê¸‰ëœ ê²ƒë“¤)

### ì‚¬í›„ ê´€ë¦¬ (D+1 to D+7)

#### Day 1 (Oct 31)
- [ ] Tier 1 ì´ë©”ì¼ ë°œì†¡ (ì•„ì¹¨ 9ì‹œ, ì˜ì–´)
- [ ] LinkedIn connection request (ê°„ë‹¨í•œ ë©”ì‹œì§€ í¬í•¨)

#### Day 2 (Nov 1)
- [ ] OHAMR website ìž¬í™•ì¸ (call pre-announcement ì²´í¬)
- [ ] Cho lab website ë°©ë¬¸, recent updates í™•ì¸

#### Day 3 (Nov 2)
- [ ] Tier 2 ì´ë©”ì¼ ë°œì†¡
- [ ] Workshop ìš”ì•½ì„ lab meetingì—ì„œ ë°œí‘œ (ì¤€ë¹„)

#### Week 1 (Nov 7ê¹Œì§€)
- [ ] Response ë°›ì€ ì´ë©”ì¼ì— íšŒì‹  (proposal, meeting schedule)
- [ ] EU OHAMR mailing list ê°€ìž… (Fagerstedtì—ê²Œ ìš”ì²­)
- [ ] Potential consortium partners ë¦¬ìŠ¤íŠ¸ ì—…ë°ì´íŠ¸

---

## ðŸ“Š ì˜ˆìƒ í•™ìŠµ ì„±ê³¼

### ì§€ì‹ ìŠµë“ (Knowledge)

**Level 1: ê¸°ë³¸ ì´í•´** (ëª¨ë“  ì°¸ì„ìž)
- [ ] AMR global crisis ê·œëª¨ (2050ë…„ 1,000ë§Œ ëª…/ë…„)
- [ ] EU OHAMR êµ¬ì¡° (â‚¬253M, 30êµ­, 2025-2034)
- [ ] ì™¸ë§‰ì˜ AMR ê¸°ì—¬ (LPS permeability barrier)
- [ ] Type IV pilusì˜ ì´ì¤‘ì  ì—­í•  (virulence + vulnerability)

**Level 2: ë©”ì»¤ë‹ˆì¦˜ ì´í•´** (í¬ë‹¥/ì—°êµ¬ìž)
- [ ] SlkA/Bì˜ secretin channel blocking mechanism
- [ ] LPS/LTA ìƒí•©ì„± ê²½ë¡œ (PGM ì—­í• )
- [ ] ASMì˜ ìž‘ìš© ë©”ì»¤ë‹ˆì¦˜ (PGM inhibition â†’ membrane disruption)
- [ ] Antibiotic adjuvant ì „ëžµì˜ ì›ë¦¬

**Level 3: ì‹¬í™” ì´í•´** (ì „ë¬¸ ì—°êµ¬ìž)
- [ ] Secretin structure (dodecamer, gating)
- [ ] PGM biochemistry (Glc-1-P â‡„ Glc-6-P)
- [ ] In vivo infection model ì„¤ê³„ (bacteremia, skin infection)
- [ ] Preclinical to clinical translation pathway

### ê¸°ìˆ  ìŠµë“ (Skills)

**ì‹¤í—˜ ê¸°ìˆ **:
- [ ] Outer membrane permeability assay (NPN uptake)
- [ ] Cryo-EM sample preparation (membrane protein complex)
- [ ] In vivo efficacy testing (murine infection models)
- [ ] MIC determination & synergy testing (FIC index)

**ë¶„ì„ ê¸°ìˆ **:
- [ ] Structural bioinformatics (AlphaFold2, docking)
- [ ] Genomic surveillance (WGS, AMR gene detection)
- [ ] Metabolomics (UDP-sugar quantification, LC-MS)
- [ ] PK/PD modeling (AUC/MIC)

**Soft skills**:
- [ ] Grant writing (EU OHAMR proposal)
- [ ] International collaboration setup (MOU, IP)
- [ ] Scientific presentation analysis (what makes a good talk)
- [ ] Networking techniques (elevator pitch, follow-up)

### íƒœë„ ë³€í™” (Attitude)

**íŒ¨ëŸ¬ë‹¤ìž„ ì „í™˜**:
- [ ] AMR = multidisciplinary problem (biology + chemistry + informatics + policy)
- [ ] Membrane biologyì˜ ì¤‘ìš”ì„± ìž¬ì¸ì‹
- [ ] International collaborationì˜ í•„ìˆ˜ì„±

**ì—°êµ¬ ë°©í–¥**:
- [ ] New target identificationì— ê´€ì‹¬ ì¦ê°€
- [ ] Translational researchì˜ ì¤‘ìš”ì„± ì¸ì‹
- [ ] Industry partnership ê³ ë ¤

**ê²½ë ¥ ê°œë°œ**:
- [ ] EU grantì— ì ê·¹ì  ë„ì „
- [ ] Startup/entrepreneurship ê°€ëŠ¥ì„± ê³ ë ¤
- [ ] Global AMR network ì§„ìž… ë™ê¸°

### ë„¤íŠ¸ì›Œí¬ í™•ìž¥ (Network)

**ì§ì ‘ ì—°ê²°** (ëª©í‘œ):
- [ ] Patriq Fagerstedt (OHAMR coordinator)
- [ ] Hongbaek Cho (êµ­ë‚´ membrane biology)
- [ ] Jinki Yeom (êµ­ë‚´ AMR drug development)
- [ ] 1-2ëª… ì¶”ê°€ PI (Session 2-4ì—ì„œ)

**ê°„ì ‘ ì—°ê²°** (through Fagerstedt):
- [ ] EU AMR research network
- [ ] JPIAMR alumni
- [ ] Potential consortium partners (3-5 labs)

**ê¸°ê´€ ì—°ê²°**:
- [ ] IAMRT (ì„±ê· ê´€ëŒ€)
- [ ] A&J Science Co. (ì‚°ì—…ê³„)
- [ ] Swedish Research Council

### ì‹¤ìš©ì  ì‘ìš© (Application)

**í¬ë‹¥ ì—°êµ¬ìž**:
- [ ] EU OHAMR proposal ì•„ì´ë””ì–´ 3ê°œ ë„ì¶œ
- [ ] Slk ë˜ëŠ” PGM ê´€ë ¨ collaborative project êµ¬ìƒ
- [ ] ë‹¤ìŒ career move ê³„íš (Korea vs. EU postdoc)

**ê¸°ìˆ  ì´ì „**:
- [ ] Membrane permeability assayë¥¼ ë‚´ ì—°êµ¬ì— ë„ìž…
- [ ] AlphaFold2ë¡œ ë‚´ protein-protein interaction ì˜ˆì¸¡
- [ ] In vivo modelì„ biofilm ì—°êµ¬ì— ì ìš©

**ìž¥ê¸° ê³„íš**:
- [ ] 2026.01 OHAMR first call ì¤€ë¹„ (consortium êµ¬ì„±)
- [ ] 2026.06 Joint proposal ì œì¶œ (NRF-EU)
- [ ] 2027 EU postdoc ë˜ëŠ” PI position

### ì¸¡ì • ê°€ëŠ¥í•œ ì„±ê³¼ ì§€í‘œ

**ì¦‰ì‹œ** (Workshop í›„ 1ì¼):
- ë©”ëª¨ íŽ˜ì´ì§€ ìˆ˜: ìµœì†Œ 10íŽ˜ì´ì§€
- ëª…í•¨ êµí™˜: ìµœì†Œ 5ëª…
- ì§ˆë¬¸ ì°¸ì—¬: 1-2íšŒ

**ë‹¨ê¸°** (1ì£¼ì¼):
- Follow-up ì´ë©”ì¼ ë°œì†¡: 3-5ëª…
- LinkedIn connection: 5-7ëª…
- ì°¸ê³ ë¬¸í—Œ ë‹¤ìš´ë¡œë“œ: 10íŽ¸ ì´ìƒ

**ì¤‘ê¸°** (1ê°œì›”):
- ë…¼ë¬¸ ì½ê¸° ì™„ë£Œ: 5íŽ¸ (recommended reading)
- Lab meeting ë°œí‘œ: 1íšŒ (workshop summary)
- Collaboration ë…¼ì˜ ì‹œìž‘: 1-2ê±´

**ìž¥ê¸°** (6ê°œì›”):
- EU OHAMR proposal ì œì¶œ: 1ê±´ (ë˜ëŠ” ì°¸ì—¬)
- Joint research ì°©ìˆ˜: ê°€ëŠ¥ ì‹œ
- International conference ì°¸ì„: 1íšŒ (EU AMR meeting)

---

## ðŸ”— ì¶”ê°€ ë¦¬ì†ŒìŠ¤

### ì˜¨ë¼ì¸ ë°ì´í„°ë² ì´ìŠ¤

**AMR Databases**:
- CARD (Comprehensive Antibiotic Resistance Database): card.mcmaster.ca
- NCBI AMRFinderPlus: ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/
- ResFinder: cge.food.dtu.dk/services/ResFinder/

**Structural Resources**:
- PDB (Protein Data Bank): PilQ structures (e.g., 5WQ8)
- AlphaFold DB: alphafold.ebi.ac.uk
- EMDB (Electron Microscopy Data Bank): Secretin structures

**Surveillance**:
- WHO GLASS (Global Antimicrobial Resistance Surveillance System)
- ECDC (European CDC) AMR data
- K-GLASS (Korea)

### í•™íšŒ & ë„¤íŠ¸ì›Œí¬

**êµ­ì œ í•™íšŒ**:
- ECCMID (European Congress of Clinical Microbiology)
- ASM Microbe (American Society for Microbiology)
- ICAAC (Interscience Conference on Antimicrobial Agents)

**EU Networks**:
- JPIAMR â†’ OHAMR transition
- COMBACTE (Combatting Bacterial Resistance in Europe)
- ENABLE (European Gram-Negative Antibacterial Engine)

**í•œêµ­**:
- ëŒ€í•œë¯¸ìƒë¬¼í•™íšŒ (Korean Society for Microbiology)
- IAMRT ì„¸ë¯¸ë‚˜ (ì„±ê· ê´€ëŒ€, ê²©ì›”)
- í•­ìƒì œë‚´ì„±ì—°êµ¬íšŒ

### êµìœ¡ ìžë£Œ

**Online Courses**:
- Coursera: "Antimicrobial Stewardship" (University of Dundee)
- edX: "Bacterial Genomes: From DNA to Protein Function via Bioinformatics"
- FutureLearn: "Antimicrobial Resistance in Practice"

**YouTube Channels**:
- iBiology (Microbiology lectures)
- JPIAMR Channel (webinars, interviews)
- Wellcome Trust (AMR documentaries)

### Funding Opportunities

**EU**:
- OHAMR Joint Calls (2025.11 first)
- ERC (European Research Council) - AMR priority
- Marie Curie IF (Individual Fellowship)

**í•œêµ­**:
- NRF ì‹ ì§„ì—°êµ¬ (AMR ìš°ëŒ€)
- IITP ë°”ì´ì˜¤ì¸í¬ (AMR surveillance)
- ë²”ë¶€ì²˜ ê°ì—¼ë³‘ R&D (ì§ˆë³‘ì²­)

**êµ­ì œ í˜‘ë ¥**:
- NRF-EU Joint Call
- K-EU Innovation Hub
- ASEM (Asia-Europe Meeting) STI program

### Tools & Software

**Bioinformatics**:
- ABRicate (AMR gene screening)
- Resfams (AMR protein families)
- DeepARG (ML-based AMR prediction)

**Structural Modeling**:
- AlphaFold2 (Colab notebook)
- HADDOCK (Protein-protein docking)
- GROMACS (MD simulation)

**Data Analysis**:
- R/Bioconductor (AMR surveillance data)
- Python/Biopython (genomics)
- GraphPad Prism (MIC, survival curves)

---

**ë¬¸ì„œ ìž‘ì„±**: 2025-10-29
**ë²„ì „**: 1.0 (Comprehensive Format)
**ìž‘ì„±ìž**: Conference Preparation System
**ì›Œí¬ìƒµ**: IAMRT 2025

**Workshop ì°¸ì„ ì „ ì´ ë¬¸ì„œë¥¼ ìµœì†Œ 1íšŒ ì •ë…í•˜ê³ , ì§ˆë¬¸ 3ê°œë¥¼ ì¤€ë¹„í•˜ì„¸ìš”!**

**Good luck and enjoy the workshop! ðŸŽ‰ðŸ”¬ðŸ¦ **
